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One biological function shared by all competent proteins is the ability to fold 
properly. This function must be performed effectively before other productive functions 
are possible [l]. The growing list of diseases attributed to protein misfolding underscores 
this importance and demonstrates the consequences of ineffective folding [2, 3]. For this 
reason as well as its fundamental importance to biology, protein folding has been the 
focus of much study. How proteins achieve proper folding is still unknown. Anfinsen [ 4] 
proposed that all of the information needed for protein folding to a native active 
conformation was contained in its primary amino acid sequence. This process occurred 
spontaneously in vitro without the aid of other proteins, a concept referred to as self-
assembly. Some researchers assumed protein folding in vivo occurred spontaneously and 
unassisted as well. However, protein folding in vitro, even for simple monomeric proteins 
under optimal conditions, takes place very slowly, much more slowly than seen in vivo. 
An added complication of in vivo protein folding is molecular crowding, which may 
change reaction rates and equilibria by more than an order of magnitude resulting in 
unfavorable protein aggregation [5]. 
It is now appreciated that in vivo protein folding of some proteins (especially 
large multi-domain proteins) is greatly enhanced by other proteins called molecular 
chaperones. Molecular chaperones can facilitate protein folding usually via an ATP 
dependent mechanism, which subsequently prevents improper interactions between 
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protein surfaces that lead to non-productive protein folding pathways. The concept of 
molecular chaperones does not refute the concept of self-assembly, rather it is thought 
chaperones assist proteins in self-assembly by reducing non-productive interactions that 
might compete with self-assembly interactions in a complex cellular environment [6]. 
Most molecular chaperones are stress proteins, meaning their synthesis is upregulated 
under stress conditions such as heat shock or hypoxia. More extensive reviews of the list 
of molecular chaperones can be found in the literature [1, 3, 7-9]. Only the chaperones 
studied in this report are reviewed below: Hsp90, Hsp70, Hsp40, p6080P, FKBPs, Cyp40, 
p23, and p50cdc37• 
Hsp90 
Hsp90 structure and function 
The 90-kDa Heat Shock Protein (Hsp90) family of proteins was originally 
identified, as indicated by the name heat shock protein, as a 90-kDa protein induced by 
heat stress. Under these conditions Hsp90 aids in protein refolding of thermally denatured 
proteins and prevents irreversible thermal aggregation. This indicates the importance for 
Hsp90 function under stress conditions. However, even when cells are unstressed 
constitutively expressed Hsp90 is one of the most abundant proteins in the cell [10]. In 
most eukaryotes, two cytosolic isoforms Hsp90a and J3, have been identified. While both 
isoforms may be constitutively expressed in some cell types, Hsp90f3 is constitutively 
expressed in most cells, and Hsp90a expression is the primary isoform of Hsp90 induced 
by stress. The importance of Hsp90 for cell functions is underscored by its evolutionary 
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conservation from bacteria (called HtpG in E.coli) to higher eukaryotes. However, the 
role it plays in facilitating cellular processes may have changed over time, since Hsp90 is 
vital for eukaryotes from yeast on up, but is not essential for bacterial survival (reviewed 
by [11]). In eukaryotes, cytosolic Hsp90 is reported to function in many cellular 
processes including signal transduction, protein trafficking, chromatin condensation, cell 
cycle regulation, regulation of transcription and translation, protein degradation, and 
apoptosis [12]. Based on the abundance of Hsp90 in the cell and the multiple and varied 
functions one may expect Hsp90 to play a role in general protein folding. However, 
Hsp90 is not involved in folding of most proteins in the cell but rather seems to work on a 
select set of proteins that are critical for certain cell functions and survival. Cytosolic 
Hsp90 is the most highly expressed member of the Hsp90 gene family, but recently other 
organelle specific family members have been identified which add to the functions 
attributed to the family. Grp94/pg96 localizes to the endoplasmic reticulum and is 
involved in protein folding and transport in the ER, as well as antigen presentation to the 
major histocompatibility complex for mounting immune responses (reviewed in [13]). 
Hsp75/TRAP1 is found in the mitochondrial matrix and is also thought to function in 
transport and folding of mitochondrial proteins (reviewed in [14-16]). Hsp90 will be used 
to refer to the abundant cytosolic form and when generally referring to the whole family, 
specific members will be referred to by name when distinctions about function, structure, 
or location are necessary. 
All family members share similar structural domain organization and are therefore 
expected to act by similar mechanisms. Hsp90 functions as a homodimer. Dimerization is 
attributed to its C-terminal 191 residues [14, 17]. The N-terminal domain is highly 
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conserved and binds ATP in an unusual kinked conformation [18, 19]. Bound ATP is 
hydrolyzed, thus making it an ATPase. Structural comparisons of this domain with other 
proteins have placed Hsp90 into the GHKL superfamily of homodimeric 
ATPases/kinases including members such as DNA gyiase B, MutL, and the prokaryotic 
histidine kinases Che A and Env Z (involved in E. coli osmosensing). Proteins in this 
superfamily bind ATP by a structurally novel Bergerat fold [20, 21], which is probably 
the reason for the unusual kinked conformation of the bound nucleotide [12, 19]. Based 
on the similarity in structure to DNA gyrase and MutL a similar mechanism of action has 
been proposed in which Hsp90 is dimerized by association of its C-terminal sites. Upon 
binding ATP the N-terminal domains are induced to transiently dimerize forming a 
"molecular clamp" around the unfolded protein substrate allowing it to fold or actively 
participate in folding. The substrate protein is released when ATP hydrolysis disrupts the 
dimerization of the N-terminal domains [14, 22, 23]. This is a useful model for nucleotide 
regulated substrate binding based on the structural studies of these proteins, but more 
work is needed to determine whether Hsp90 actually facilitates protein folding through 
this mechanism. 
Evidence that is consistent with a molecular clamp model demonstrates that 
Hsp90 exists in at least two functional conformations that are regulated by nucleotide 
binding. The two functional conformations are characterized by Hsp90's affinity for 
phenyl sepharose when bound to ADP and its affinity for p23, a co-chaperone, when ATP 
is bound [24, 25]. These conformations have been further characterized by the effect of 
two Hsp90 binding drugs: benzoquinone ansamycins and molybdate. The benzoquinone 
ansamycin geldanamycin (GA) mimics the kinked conformation of the nucleotide bound 
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to Hsp90 [18, 19]. GA locks Hsp90 in an open ADP conformation with high affinity for 
phenyl sepharose. Molybdate action depends on the presence of ATP and is thought to 
bind with ADP mimicking they-phosphate of ATP after hydrolysis, locking Hsp90 into 
an Hsp90:ADP+Mo04 closed complex. Both of these conformations have characteristic 
protease fingerprints indicating distinct structural differences. Neither drug-induced 
conformation represents a productive folding complex, however, as indicated for the 
p561ck kinase substrate [26, 27]. 
Two other structures identified in the cytosolic Hsp90 protein sequence are: a 
variable charged region and the MEEVD sequence at the C-terminus. The charged region 
is variable in sequence and length between family members, being completely absent in 
bacterial HtpG and Hsp75/TRAP, and separates the N-terminal ATPase domain from the 
conserved middle domain (M). One report indicates this region may function in 
regulating peptide substrate binding, although it is not vital for Hsp90 folding of 
transfected steroid receptors in yeast [28, 29]. The MEEVD sequence is conserved and is 
important for TPR (tetratricopeptide repeat) containing co-chaperone associations (to be 
discussed later). A graphical representation of the Hsp90 domain organization is shown 
below. The actual substrate binding site has not been identified although reports of both 
€ 
N-terminal and C-terminal substrate binding may indicate that there is more than one site 
[30]. This may explain why Hsp90 has such a diverse clientele (see Table 1) and may 
allow it to be more adaptable to client folding requirements. It also may explain the 
failure to identify a consensus binding motif among its clients. The only consistent theme 
to Hsp90 clients, to date, is that most are multi-domain regulatory signal transduction 
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proteins that can adopt more than one conformation, thus designating Hsp90 the "signal 
transduction chaperone". 
ATPase Charged 
N-terminal domain Middle domain 




During active (ATP dependent) chaperoning Hsp90 associates with several 
protein cohorts or co-chaperones forming more than one large multicomponent chaperone 
complex. For the most part these co-chaperones appear to bind and dissociate in an 
ordered ATP dependent fashion [31-34]. This has come to be known as the Hsp90 
chaperone cycle [11]. Certainly some Hsp90 substrates are folded by a cycle of Hsp90 
and co-chaperone binding and release; however, it is important to point out that Hsp90 
does not nescessarily interact the same with each substrate. In fact, it is useful to compare 
Hsp90/substrate interactions and to exploit differences to learn more about function. The 
Hsp90 chaperone cycle model is based mostly on reconstitution studies of the steroid 
hormone receptor family of substrates (see Figure 1). These studies indicate that during 
biogenesis to a steroid binding state Hsp70 and its co-chaperone Hsp40 bind the receptor 
forming the "early complex" [11, 34-37]. After an initial step where Hsp70 hydrolyzes 
ATP and Hsp40 is released, the co-chaperone p60HOP (Stil in yeast) associates with the 
complex [31, 32, 34, 38]. P60HOP interacts with Hsp70 through its N-terminal TPRl 
domain. P60HOP also interacts with Hsp90 via its central TPR2A domain forming a 
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large Hsp70•p60HOP•Hsp90 complex called the "intermediate complex" [11, 34, 39, 
40]. In this complex the steroid receptor passes from Hsp70 to Hsp90. The Hsp70 and 
p60HOP are replaced by at least one TPR containing immunophilin per Hsp90 monomer 
(FKBP51, FKBP52, or Cyclophilin 40) and the acidic p23 protein in the "late complex" 
[11, 41, 42]. Previous reports indicate that for kinase substrates, the kinase specific co-
chaperone p50cdc37 is substituted for the immunophilin component [43, 44]; however, 
work presented in chapter 2 indicates that is not necessarily true [45, 46]. Also at least 
one steroid receptor, androgen (AR), forms a complex with p50cdc37 [47]. The mature 
complex is thought to keep the steroid receptors in a conformation capable of binding 
hormone but incapable of binding DNA as a transcription factor. In the presence of 
hormone, Hsp90 complex dissociation correlates with the formation of an active ligand 
bound receptor dimer. 
As mentioned above Hsp90 interacts with several different proteins during 
folding. These proteins are thought to assist Hsp90 in ATP dependent client folding. All 
except Hsp70 and Hsp40 are referred to as Hsp90 cohorts or co-chaperones. 
Independently many co-chaperones facilitate protein folding or refolding indicating their 
importance may not be limited to Hsp90 mediated folding. The functions they play in 
Hsp90 mediated folding are just now being determined and are still largely unknown. 
More work is required to determine how they influence Hsp90 functions. To provide 
more detailed information for future reference a short section about each Hsp90 partner 
protein is included. 
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Figure 1. Hsp90 Chaperone Cycle Involved in Steroid Hormone Receptor (SHR) Folding 
and Activation. 
Steroid receptors form heterocomplexes with many chaperones and co-chaperones 
in an ordered ATP dependent manner. The first components found to bind are 
Hsp70 and Hsp40 forming the "Early complex". Hsp90 is shown as a dimer. 
p60HOP also forms a dimer but only the monomer is shown for clarity. These 
components bind to form a second "Intermediate complex". Hsp70 hydrolyzes 
ATP during its binding and release of the SHR substrates. Both Hsp90 and Hsp70 
have ADP bound in the intermediate complex. Hsp70 and p60HOP are released 
and p23 and immunophilins (IP) bind to form the "Late complex" in an ATP 
dependent step. Geldanamycin (GA) is shown as inhibiting the formation of the 
"Late complex". ATP is hydrolyzed and SHR is released and if hormone is not 
present (H) the cycle starts again. If hormone is present the receptor binds and 
becomes chaperone independent and able to bind DNA as a trascription factor. 
MoO 4 is shown as inhibiting the release of SHR from the "Late complex". MoO 4 














Hsp70 and Hsp 40 
Like Hsp90, Hsp70 is just one member of a large family of proteins. Hsp70 
facilitates ATP dependent protein folding in the cytosol of both prokaryotes and 
eukaryotes under stress and unstressed conditions. The reported functions of Hsp70 are 
wide and varied and include protein trafficking, apoptosis, protein degradation, 
translocation across membranes, regulation of transcription and translation, vesicle 
uncoating, and signal transduction [48]. Unlike Hsp90, Hsp70 is thought to play a more 
generic role in de nova protein folding, interacting with many folding substrates co-
translationally [49-51]. An Hsp70 consensus binding motif has been identified indicating 
that a short hydrophobic stretch of amino acids in an extended conformation followed by 
a short region of basic residues provides a high affinity binding site for Hsp70 [52-54]. 
Estimates of the number of Hsp70 binding sites in the average protein (based on the 
common occurrence of amino acids for proteins in sequence databases) predict several 
sites per protein [55, 56]. This is consistent with a role for Hsp70 in general protein 
folding. Experimental evidence indicates Hsp70 dependent folding, while more common 
than Hsp90 mediated folding, is not as common as predicted [57] and actual cellular 
interactions and functions are more regulated (reviewed in [58]). Hsp70 regulated 
substrate folding is controlled by its co-chaperones, similar to Hsp90. There are several 
Hsp70 co-chaperones, but only Hsp40/DnaJ is reviewed here. 
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Hsp40 is a eukaryotic member of the DnaJ (E. coli Hsp40) family of proteins that 
are characterized by the presence of a conserved N-terminal I-domain. The I-domain 
meditates Hsp40's interaction with Hsp70. In E.coli the homolog DnaJ stimulates DnaK 
(E. coli Hsp70) ATPase activity and modulates substrate binding. Hsp70 chaperone 
function is referred to as a cycle of ATP regulated substrate binding and release much 
like the two state model of Hsp90. The ATP-bound open conformation of Hsp70 has a 
low affinity for substrate allowing rapid exchange. The ADP-bound closed conformation 
of Hsp70 has high affinity for substrate and a very slow exchange rate. It is thought that 
Hsp40 first binds the substrate in an ATP independent manner and conveys it to Hsp70 as 
the first step in the cycle. The Hsp40-substrate complex associates with Hsp70 via the I-
domain interaction. Hsp40 can bind Hsp70 in either state although the exchange rate of 
substrate with the ATP-bound Hsp70 is higher and is therefore favored. Once the 
substrate is transferred to Hsp70 the ability of Hsp40 to stimulate ATPase activity 
converts Hsp70 into an ADP-bound high substrate affinity and slow exchange state, 
allowing prolonged interaction and folding. In E. coli an additional co-chaperone, GrpE, 
exchanges DnaK bound ADP for ATP stimulating substrate release and completing the 
cycle. A GrpE homolog in eukaryotes has not been identified suggesting the ADP 
exchange occurs independently or by some other mechanism. However, both 
p60/STI1/HOP and Bagl/RAP46 promote ADP dissociation and exchange for ATP, 
making them potential functional homologs even though they do not replace GrpE 
function in bactieria. 
Hsp40 substra\e binding is attributed to its C-terminal domain, which is variable 
among family members. The C-terminal domain variability is thought to impart substrate 
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specificity and regulation to the Hsp70 folding cycle. Since the DnaJ family of 
chaperones is large (over 150 proteins so far) there is potential for functional diversity in 
Hsp70 machinery as well [58]. Eukaryotic Hsp40 alone assists in processes such as 
steroid hormone receptor folding and regulation, co-translational folding, protein 
renaturation, tumor suppression, and cell cycle regulation [36, 37, 59-62]. Other DnaJ 
proteins may allow Hsp70 to function in other processes. 
P60/HOP/STIJ 
P60/HOP (HOP-Hsp70/Hsp90 Organizing Protein) was originally identified as 
the nonessential yeast protein STil (stress inducible mediator of heat shock 
response)[63]. Later its human homolog, up regulated in SV40-transformed cells, was 
reported to contain several tetratricopeptide repeat (TPR) motifs, a degenerative 34 amino 
acid repeat motif reportedly involved in facilitating protein-protein interactions [64, 65]. 
In the convergent field of steroid hormone receptor research a 60kDa protein, later 
identified as a STil homolog, was isolated from receptor complexes [66]. P60/HOP is 
composed almost totally of TPR domains, nine motifs divided into three domains (TPRl 
composed of 3 motifs and TPR2A and B composed of 3 motifs each). TPR domains are 
composed of three or more TPR motifs usually in tandem but sometimes separated or 
overlapping. Structural studies indicate a cradle structure of seven a-helices in which the 
conserved EEVD motifs of Hsp70 and Hsp90 bind by multiple electrostatic interactions. 
The TPRl N-terminal domain binds Hsp70 and the TPR2A middle domain binds Hsp90 
and can do so simultaneously [38, 40, 67, 68]. Additional hydrophobic interactions with 
residues N-terminal of the EEVD motif determine the binding specificity of each domain 
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for Hsp70 or Hsp90 [40]. The C-terminal EEVD motif mediates the binding of several 
TPR containing proteins in addition to P60HOP (see below). 
The EEVD motif represents the minimal sequence for strong binding of TPR 
proteins. Other contact points of TPR co-chaperones have been suggested which regulate 
the ATPase, and therefore folding, activity of each of these proteins. P60HOP inhibits 
Hsp90 ATPase activity and favors binding to the open ADP-bound conformation [69]. It 
also favors binding to the closed ADP-bound form of Hsp70. These two conformations 
represent the opposite affinity states for substrate binding, and since p60HOP stimulates 
Hsp70 ADP exchange for ATP it is thought substrate transfer from Hsp70 to Hsp90 is 
stimulated as well. Hsp90 then quickly converts to an ATP-tight binding conformation, 
which in addition possibly causes co-factor exchange. It is important to point out that 
p60HOP forms homodimers that may bind homodimers of Hsp90 [69] but does not 
necessarily exclude the possibility of more than one TPR containing co-chaperone in 
complex with Hsp90 dimers forming mixed complexes. 
Other TPR Co-chaperones 
There are several Hsp70 and Hsp90 co-chaperones other than p60HOP that have 
TPR domains. Very little is known about the functions they have or impart to the 
chaperone complexes. The TPR proteins reviewed here are mostly Hsp90 co-harts. One 
family of TPR containing co-chaperones is called the high molecular weight 
immunophilins. In addition to containing TPR domains (composed of 3 TPR motifs), 
immunophilins also include a peptidylprolyl cis-trans isomerase (PPiases) domain that 
catalyzes the cis-trans isomerization of peptide bonds preceding praline residues. 
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Immunophilins are grouped into two structurally unrelated classes based on their ability 
to bind one of two immunosuppressive drugs that inhibit the isomerase activity. The 
cyclophilin (Cyp) class binds cyclosphorin A (CsA). The main member of interest for 
Hsp90 interaction is Cyp40 (its calculated molecular weight is 40 kDa). FKBP (FK506 
Binding Proteins) proteins bind to the compounds FK506 and rapamycin, and include the 
Hsp90 binding members FKBP51 and FKBP52 (also identified by their calculated 
molecular weights) [70]. The function of these proteins in Hsp90 complexes is unknown, 
although all have been found in both native (substrate free) and steroid hormone bound 
Hsp90 complexes. One report suggests that there are two immunophilin binding sites in 
each Hsp90 dimer [71]. Heterocomplexes with two different immunophilin components 
have not been reported and in fact there are reports of competition between the different 
immunophilins for binding to Hsp90 [72]. Initially, a catalytic role was assumed where 
the immunophilin is recruited to the Hsp90/substrate complex by the TPR domain and 
subsequently catalyzes the slow cis-trans isomerization of peptidylprolyl bonds; however, 
inhibition of the PPlase activity by CsA and/or FK506 did not have an effect on Hsp90 
interaction or folding of the glucocorticoid receptor [73]. Mutation of residues in the 
PPiase domain necessary for PPiase activity of the yeast Cyp40 (Cpr7) had no effect on 
GR activity when transfected into yeast. Therefore, the role of the PPiase domain in 
Hsp90 folding is in question, since the TPR domain and flanking regions appear to be 
sufficient for complex assembly and folding of the steroid receptor substrates [74]. 
A role in receptor attachment and trafficking has been proposed for the 
immunophilins [75, 76]. Cyp40 and FKBP52 both localize to the nucleus and may be the 
components of the Hsp90 complex that target the receptor transcription factors to the 
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nucleus. FKBP52 also interacts with the cytoskeletal associated motor protein dynein 
[77]. 
Another Hsp90 associated TPR containing protein is the Protein-serine/threonine 
Phosphatase 5 (PPS). PPS has an N-terminal TPR domain composed of four TPR motifs 
and a C-terminal phosphatase domain that can catalyze the transfer of a phosphate group 
off of serine or threonine residues (reviewed in [78]). It is not known what role PPS plays 
in the Hsp90 machinery, although an obvious possibility is to catalyze the 
dephosphorylation of either Hsp90 or Hsp90 associated proteins (co-hort or client). A 
recent report suggests this is a definite possibility for the regulation of the Hsp90 client 
the Heme-Regulated Inhibitor (HRI) of protein synthesis, an eIF2a kinase [79]. 
A final TPR containing Hsp90 associated protein is CHIP (carboxyl terminus of 
Hsc70-interacting protein). CHIP was originally identified as a protein that interacted 
with the C-terminus of Hsc70 [80]. Later it was found to also bind Hsp90 and to contain 
an U-box E3 ubiquitin ligase domain that could catalyze the ubiquitination of chaperone 
substrates. A proposed role in targeting Hsp90 and Hsp70 substrates to degradation by 
the proteasome has since been proposed especially in the presence of chaperone 
inhibiting drugs [81, 82]. 
Several other TPR containing Hsp90 co-horts have been identified, but defined 
roles in Hsp90 mediated folding of substrates have not been demonstrated. Several 
proposed functions have been suggested ranging from regulating Hsp90 ATPase activity 
to trafficking substrates to specific locations in the cell to targeting substrates for 
degradation. There is still much work that needs to be done to determine the functions 
and new protein clients and co-horts are still being identified. 
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Protein 23 
p23 was originally identified as a novel 23-kDa acidic protein associated with the 
unactivated progesterone receptor (PR) complex. In addition to p23, PR complexes 
contained Hsp90, FKBP51 and 52, and Cyp40 [83]. p23 had no sequence homology to 
heat shock proteins or immunophilins or to any other protein known at that time [84]. 
Immune isolation of p23 from rabbit reticulocyte lysate (RRL) in the absence of receptor, 
also isolate Hsp90 and the immunophilins indicating p23 functions as part of the Hsp90 
machinery [ 42]. Since then p23 has been found in association with several other 
Hsp90/client complexes [45, 85]. Depletion of p23 from RRL prevented the assembly of 
PR complexes competent to bind hormone. Addition of purified p23 restored this activity 
to RRL, suggesting p23 is an essential component of the Hsp90 machinery in RRL [42]. 
This essential function may have developed in higher organism, however, since deletion 
of p23 from yeast only mildly affects growth and folding of exogenous Hsp90-dependent 
steroid receptors or kinases [86-88]. 
The function of p23 in Hsp90 chaperoning is unknown. However, it is interesting 
to note that unlike many other Hsp90 co-horts, p23 binds only to ATP-bound Hsp90. 
ATP hydrolysis does not appear to be necessary for binding since non-hyrolyzable ATP 
analogs stabilize the substrate free Hsp90-p23 complex. In support for p23 association 
with the ATP-bound Hsp90, GA disrupts the p23 complex with Hsp90 and substrate. 
Molybdate also stabilizes the Hsp90-p23 complex and can do so when substrate is 
present. Formation of this complex requires the hydrolysis of ATP. In the absence of 
stabilizing agents the p23 association with Hsp90 and client are usually sensitive to salt 
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(0.5 M KCl) and heat (37 °C) [89]. In fact detection of the p23 component with PR was 
not seen until rapid and gentle techniques were used, and isolation of this complex is now 
often done in the presence of molybdate. 
Even though the function of p23 in the Hsp90 machinery is unknown some 
reports have suggested p23 is involved in stabilizing a conformational state of Hsp90 that 
is necessary for folding [88]. Others propose that p23 stimulates client substrate release 
from Hsp90 upon ATP hydrolysis [90]. Some Hsp90 independent activities of p23 have 
also been identified recently,such as interacting with DNA cytosine-5 methyltransferase 
[91]. Also, p23 was recently identified as a cytosolic glutathione (GSH)-dependent 
prostaglandin E2 synthase [92]. These activities may or may not be related to p23 
function in the Hsp90 complex. 
The kinase targeting p50Cdc37 chaperone 
p5oct1c37 was originally identified in yeast as a cell division cycle (cdc) mutant that 
caused cell cycle arrest at Start in G 1 [93]. In another field of research, a 50-kDa protein 
that interacted with viral transforming kinase complexes in association with Hsp90 was 
also identified [94]. It was not until homologs in Drosophila and mammals were 
identified as the 50-kDa protein associated with Hsp90 and kinases that the two fields 
merged. p50cdc37 forms complexes with Hsp90 independently and with several kinase 
substrates, including the Cdc28 kinase, Cdk4, Raf, members of the Src kinase family, 
Mpslp, HRI, and the sevenless receptor tyrosin kinase [46, 95-98]. Both Hsp90 and 
p5oct1c37 bind directly to the kinase domains of these substrate kinases [44, 99, 100]. 
Studies on truncation mutants localize Hsp90 interaction to sites in the C-terminal half of 
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the protein and kinase interaction sites in the N-terminal half of the protein. While the 
ability of p50cdc37 to bind kinases directly is thought to be the determining factor in 
formation of Hsp90 complexes with kinase substrates, Hsp90 can also bind kinases 
independent of p5oct1c37_ The two proteins appear to participate actively in kinase folding 
as indicated by increased kinase activity in response to stimulation in the presence of 
extra p50cdc37 [99, 100]. Loss of p50ct1c37 activity resulted in loss of Hsp90 from kinase 
complexes and decreased half-life [99, 101]. GA treatment also disrupts the formation of 
salt stable Hsp90/p50cdc37fkinase complex; however, it does not disrupt the native 
complex formed between Hsp90 and p50cdc37 [99]. These results suggest that each protein 
may regulate the others ability to form functional complexes with kinase clients. 
While p50cac37 ability to associate with and help fold kinases is well documented, 
the mechanism by which it facilitates kinase folding still remains unknown. A recent 
report suggesting that p50cdc37 regulates Hsp90 ATPase activity may provide.some insight 
[102]. Also the identification of a new p50cdc37 related protein (HARC) suggests a larger 
family of proteins with similar function and may allow for further characterization of 
their functions [103]. 
Hsp90 clients/substrates 
Proteins folded or chaperoned by Hsp90 and associated co-chaperones are called 
"Hsp90 clients" or "Hsp90 substrates". The protein substrates for Hsp90 are structurally 
and functionally diverse. Two of the groups of Hsp90 substrates have been mentioned 
extensively above: steroid hormone receptors and protein kinases. The steroid receptors 
are sometimes grouped with other transcription factor substrates. A third group of 
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proteins are unrelated to the first two groups or even to each other and therefore are 
labeled as "other". Table 1 shows a representative listing and classification of some 
known Hsp90 clients. Most of these substrates are regulatory proteins of some type, 
although, this is only a very loose generalization and does not lend itself to clear 
identifying structural or functional characteristics common to all. Kinase folding by 
Hsp90 machinery is the focus of this report, specifically folding of the Src-family 
member p561ck (56:-kDa lymphoid cell specific kinase) and to a lesser degree the Heme-
Regulated Inhibitor of protein synthesis [the heme-regulated eIF2a kinase (HRI)]. 
Results are compared to the work on steroid receptors, since their interactions with Hsp90 
machinery have been more thoroughly characterized. Pharmacological inhibition of 
Hsp90 and Hsp70 is also used to dissect the roles of chaperones in kinase biogenesis both 
in vivo and in vitro. The introduction of pharmacological intervention in the field of 
chaperone study, especially with the advent of the specific Hsp90 inhibitor GA, has 
recently and rapidly allowed dramatic growth in our understanding of Hsp90 processes. 
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CHAPTER2 
EFFECTS OF GELDANAMYCIN, AN HSP 90-BINDING AGENT, ONT CELL 
FUNCTION AND THE NONRECEPTOR PROTEIN TYROSINE KINASE p561ck 
Introduction 
The class of benzoquinone ansamycin compounds is currently under investigation 
in many areas of molecular biological research. Early work with geldanamycin (GA) and 
· herbimycin A identified them as active antibiotic and herbicidal metabolites from 
bacteria [104, 105]. Later work suggested they might be specific inhibitors of the Src-
family of protein tyrosine kinases [106, 107]. However, not all of their biological 
activities could be attributed to their ability to inhibit kinases [108]. Early on these 
compounds were recognized for their ability to inhibit transformed tumor cell growth and 
their ability to induce differentiation of some cell lines [107, 109]. Not until relatively 
recently though was their molecular target, Hsp90, and mode of action, Hsp90 inhibition, 
identified [19, 110, 111]. 
Since the identification of Hsp90 as the molecular target of GA and Herbimycin 
A the effects of treatment with these compounds on various Hsp90 clients have been the 
subject of many studies. Specific effects have been reported on many Hsp90 dependent 
proteins such as steroid receptors, the Raf-1 serine/theronine kinase, mutant forms of the 
p53 tumor suppressor protein, both viral and cellular Src-family kinases (p60src and 
p561c~, eIF2a kinases (HRI), ErbB-2 (HER-2/neu). Many of the Hsp90 substrates are 
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important for cell growth and some are found to promote unregulated growth typical of 
cancer cells [112-116]. One of the effects of these Hsp90 binding drugs is to inhibit the 
stable interactions between Hsp90 and substrate. When these complexes are disrupted 
often there is an associated degradation of the client usually by the proteasome [117-120]. 
Since many growth-promoting proteins depend on Hsp90, induction of degradation of 
these proteins by treatment with GA or herbimycin A often results in growth inhibition or 
apoptotic cell death. Other than Hsp90's ability to chaperone many growth promoting 
and sometimes tumor promoting proteins, Hsp90 has also been linked to resistance of 
some cancer cells to chemotherapy. This has been related to Hsp90' s ability to stabilize 
activated and often mutated versions of proteins that produce the resistance phenotype 
[121, 122]. Along with this, Hsp90 is over-expressed in a wide variety of cancer and 
virally transformed cells, possibly due to a dependence that these cells have on one or 
more Hsp90 dependent proteins [123-125]. In order to attack multiple targets and 
especially target proteins involved in the multi-drug resistance of tumor cells, Hsp90 has 
been identified as a novel target in cancer therapy, either as a single agent or in 
combination with other drugs. Currently the GA derivative 17-allylaminogeldanamycin is 
in phase I clinical trials as a single agent and implicated for further study in combination 
with other drugs. 
Studies of the effects of drug treatment in immune cell systems are also important. 
An acknowledged side effect of many cancer therapies is cytotoxicity especially to cells 
of the immune system [125]. For this reason some of these drugs have also been studied 
as potential immunosuppresants. One study has characterized the effects of GA and 
herbimycin A on T cell activation response via the antigen T cell receptor (TCR) and 
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CD28, which are involved in co-stimulation of TCR activated T cells. June et al. [126] 
reported that pretreatment of TCR activated peripheral mononuclear cell cultures with 
herbimycin A, inhibited proliferation, interleukin2 (IL-2) and IL-2 receptor (IL-
2R/CD25) production, inositol 1,4,5-triphosphate release (tested only in the Jurkat T cell 
line), mobilization of Ca2+ cellular stores (tested only in the Jurkat T cell line), and a 
general protein tyrosine kinase activity. T cells produce an Hsp90 dependent T cell 
specific protein tyrosine kinase p561ck [56-kDa lymphoid cell kinase], which is necessary 
for signal transduction by many cell surface receptors, such as the T cell receptor (TCR), 
the IL-2R (CD25), and CD28, and has been the focus of research in our lab for many 
years. June et al. [126] also characterized the effects of herbimycin A on both p561ck and 
p5g/Yn, another protein tyrosine kinase in T cells. In these cells herbimycin A depleted the 
cellular levels of both proteins in overnight treatments. In order to better our 
understanding of the effects of these drugs and to expand on the work mentioned above, 
studies were conducted in both model cultured T cells and primary isolated T cells are 
presented here. Results from these studies indicate that different cell populations show a 
concentration and cell type specific sensitivity to GA both in viability and activation 
response. Also different populations of the Hsp90 dependent p561ck kinase respond to 
drug treatment with variable sensitivities to degradation. Finally, a previously identified 
pathway for GA mediated degradation for other Hsp90 clients is challenged by results for 
p56lck. 
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Materials and Methods 
Materials 
The E6.l and J.CaMl.6 Jurkat human leukemia T cell lines that produce either 
full-length p561ck or a truncated protein product, respectively, were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA.). Splenic mononuclear cells 
were isolated from 7-week-old male DBA mice (Sprague Dawley, Indianapolis, IN.) All 
experiments on splenic mononuclear cells were provided by collaboration with Peter 
Yorgin (Stanford University, Palo Alto, CA.). RPMI 1640 cell culture media, penicillin, 
streptomycin, and sodium bicarbonate were purchased from Sigma Chemical Company 
(St. Louis, MO.). L-glutamax was purchased from Gibco Life Science. Fetal Bovine 
Serum (FBS) was purchased from Hyclone (UT.). Geldanamycin (GA) (m.w. = 560g/mol 
provided by the Drug Synthesis and Chemistry Branch of the Developmental 
Therapeutics Program, Division of Cancer Treatment, National Cancer Institute) was 
prepared in dimethyl sulfoxide (DMSO, Sigma Chemical Co. St. Louis, MO.). 
Lactacystin and clasto-lactacystin f3-lactone (purchased from Calbiochem, La Jolla, CA.) 
were also prepared in DMSO. DMSO was used as a vehicle control in these experiments. 
Bafilomycin A was provided by Peter Yorgin. Anti-p561ck polyclonal antibodies were 
prepared as ascites fluid from mice or rabbits immunized with purified recombinant 
histidine-tagged human p561ck (provided by Dr. Paul Burn, Hoffmann-LaRoche, Nutley, 
N.J.) by the Hybridoma Center for the Agricultural and Biological Sciences (Oklahoma 
State University, Stillwater, OK.). Antibody specificity was verified by the ability to 
western blot and immuno-precipitate full-length radiolabeled p561ck from E6.l Jurkat T 
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cell lysates but not from J.CaMl.6 Jurkat T cell lysates. Anti-actin antibodies were 
provided by Peter Yorgin. Anti-ubiquitin antibodies were purchased from Sigma. Anti-
mouse immunoresin was prepared by coupling goat anti-mouse IgG (Jackson-
Immunologicals) to p-Nitrophenyl Chloroformate-activated agarose (Sigma). Pansorbin 
was purchased from Calbiochem. Nitrocellulose and polyvinyldiflouride (PVDF) were 
purchased from Bio-Rad (CA.) Immunoblotting blotting reagents nitro-blue tetrazolium 
(NBT) and bromo-chloro-indolyl-phosphate (BCIP) were purchased from Sigma 
Chemical Company for detection of either anti-mouse or anti-rabbit secondary antibodies 
conjugated with alkaline phosphatase (Jackson Immunologicals). 
T cell culture 
Experiments carried out on primary T cells were done in collaboration with Dr. 
Peter D. Yorgin, Abdul M. Fellah, Emmanuel Katsanis, Jeff M. Couchman, and Luke 
Whitesell in the Department of Pediatrics, Steele Memorial Children's Research Center, 
University of Arizona, Tuscon, AZ. 85724 as described previously [127]. Briefly, splenic 
mononuclear cells were isolated from 7 week-old male DBA mice (Sprague Dawley, 
Indianapolis, IN.) by density-gradient centrifugation of spleen homogenates in 
Lympholyte M (Cedar Lane Laboratories, Ontario, Canada). Isolated mononuclear cells 
were cultured in RPMI 1640 supplemented with FBS to 10%, 2 mM L-glutamine, 50 IU 
penicillin, 50 µglml streptomycin, 100 ng/L gentamycin, 1 mM sodium pyruvate, lx 
nonessential amino acids, and 50 µM mercaptoethanol. Activated T cells were prepared 
by stimulation of isolated splenic mononuclear cell cultures with 100 U/ml IL-2 (from 
Dr. Emmanuel Akporiaye, University of Arizona, Tuscon, AZ.), or 0.5 µglml Con A, or 
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10 U/ml IL-2 and 0.5 µglml Con A for 72 hours prior to addition of GA or DMSO. A 
predominant T cell population results from culture of mononuclear cells with Con A for 
48 hours. Results of these experiments are presented in this dissertation, as they provide 
part of the context in which results from my experiments are interpreted. 
Jurkat T cell lines, both E6.l and J.CaMl.6, were cultured in RPMI 1640 
supplemented with 24 mM sodium bicarbonate, 2 mM L-glutamine, 50 IU penicillin, 50 
µglml streptomycin, and FBS to 10%, and pH was adjusted to 7.0. Cultures were 
maintained in a humidified 5% CO2 atmosphere at 37°C. Duration and cell density are 
indicated for each experiment. 
Jurkat T cell and splenic mononuclear cell viability, growth, and activation 
Jurkat T cells were cultured for indicated times in the presence or absence of 
indicated concentrations of GA. Culture growth was monitored by counting aliquots of 
the culture on a hemocytometer grid (dimensions of lxlxlmm). 5-10 replicate counts 
were averaged and standard deviations calculated for each condition. Viability was 
assessed by the ability of cells to exclude the vital dye trypan blue (Sigma). Percent 
viability was calculated by multiplying the ratio of the average number of vital cells for a 
given condition over the average total number of cells by 100. The average percent 
viability and growth were calculated from the averages of 13 experiments. Percent 
growth was calculated by multiplying the ratio of culture density for a given condition 
over the culture culture density for the drug vehicle control (DMSO) by 100. 
The two-time point GA dose curve was counted, viability was assessed and 
standard deviations were calculated for 5 replicate counts, as described above, and 
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represents a typical experiment used to calculated the averages described above. 
Student's t test was used to analyze significant differences. Differences were considered 
significant when the p value was< 0.05 indicating a confidence level greater than 95%. 
Viability of resting splenic mononuclear cells was assessed similarly to Jurkat T 
cells. Since resting mononuclear cells represent a mixed population in order to ensure that 
the viability of lymphocytes was being determined, trypan blue staining was used in 
conjunction with cell sorting by a flow cytometer. Two experiments with six replicates 
each were counted and stained with trypan blue during exposure to GA. Splenic 
mononuclear cells preactivated with IL-2 and Con A were treated with GA for 18 hours 
and viability was assessed as described above. 
To determine whether late addition of GA to splenic mononuclear cells 
preactivated with IL-2, Con A, or both would inhibit subsequent proliferation, cells were 
activated as described above and growth was monitored by incorporation of 
[ 3H]thymidine. After 72 hours of mitogen stimulation by Con A and/or IL-2, GA, DMSO 
control, or no treatment control (RPMI 1640) were added to cultures concomitantly with 
1 µCi of [3H]thymidine. Cells were incubated for 15 hours and harvested on glass-fiber 
filters and incorporation of [3H]thymidine was determined by liquid scintillation 
counting. A stimulation index was calculated as the ratio of [3H]thymidine incorporated 
by cells under a given condition over [3H]thymidine incorporated by cells in media with 
no treatment. Three experiments with 6 replicates each were used for statistical analysis. 
Differences in viability and growth stimulation between conditions were analyzed using 
the Student's t test as stated above. 
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Splenic mononuclear cells were stimulated to produce IL-2 and IL-2 receptor (IL-
2R/CD25) in response to treatment with anti-CD3 (TCR) and anti-CD28 antibodies 
resulting in receptor stimulation. Production of IL-2 and IL-2R were monitored after 
culture for 15 hours in the presence and absence of pretreatment with 1.7 µM GA, 
followed by a wash and then 18 hours stimulation with antibodies. lL-2 secretion in the 
media of stimulated cells was compared between treatments by determining the dilutions 
needed to achieve 50% of the maximum incorporation of [3H]thymidine in the murine IL-
2 dependent cytolytic T lymphocyte line (CTLL-2, from ATCC) [128, 129]. Culture 
supematants were prepared in 96 well plates as three fold serial dilutions. 2 x 104 
prewashed CTLL-2 cells were added per well. Plates were incubated for 15 hours under 
standard culture conditions and then exposed to 2 µCi [3H]thymidine for 6 hours before 
being harvested and counted on a scintillation counter. lL-2 concentrations were 
determined by comparison to a standard curve for known IL-2 concentrations. IL-
2R/CD25 production in response to CD3/CD28 stimulation was quantified using flow 
cytometry to detect FITC conjugated anti-CD25 antibody (PharMingen) binding to the 
cells. Assays were preformed three times for statistical analysis. 
Cell lysis and p561ck detection 
Resting or activated splenic mononuclear cells were treated with GA for the 
indicated time and then lysed in PBS supplemented with 10% glycerol, 1 % Tween-20, 12 
mM sodium deoxycholic acid, 0.1 % SDS, 1 mg/L phenyl-methyl-sulfonyl-fluoride, 200 
µ,g!L aprotinin, and 200 µ,g/L leupeptin) and clarified at 14000 x g for 20 minutes at 4°C. 
Protein concentrations were determined relative to a standard curve for BSA using the 
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BCA assay kit (Pierce). Cell lysates were separated by SDS-PAGE, transferred to 
nitrocellulose membranes, and immunostained for p561ck using the chemiluminescent 
horseradish peroxidase substrate, Luminol, and exposure to autoradiography film. p561ck 
levels were quantified by scanning computer densitometry. 
Similarly, suspension cultures of Jurkat T cells were treated with GA as indicated 
and harvested by a single 400 x g centrifugation without washing, as it was determined 
there was significant loss of cells due to washing GA treated cells. Whole cell lysates 
were prepared by lysing cells in boiling 2X SDS-PAGE sample buffer [125 mM Tris-HCl 
(pH 6.8), 10% SDS, 55 mg/ml dithiothreitol, 10% glycerol, 0.005% bromphenol blue] 
[130]. For immunoprecipitations and to analyze detergent solubility of p561c\ cells were 
lysed by rocking in RIPA lysis buffer (10 mM sodium phosphate pH 7.4, 150 mM 
sodium chloride, 0.1 % SDS, 2% Triton X-100, 0.76% sodium deoxycholic acid, 2.5 mM 
EDTA, 1 mM EGTA, 50 mM sodium fluoride, 1 mM sodium vanadate, 200 µg/L 
aprotinin, 17 mg/L phenyl-methyl-sulfonyl fluoride, 1 mM dithiothreitol, 2 mg/L 
leupeptin) for 30 minutes at 4°C. Lysates were clarified by centrifugation at 14000 x g for 
5 minutes at 4 °C. Supernatants were either separated by SDS-P AGE or immuno-
precipitated for 1 hour at 4 °C with Santa Cruz biologicals anti-p561ck polyclonal or 
MOPC-21 non-immune antibodies (Sigma) pre-bound to anti-IgG coupled agarose. 
Detergent (RIPA)-insoluble pellets were monitored by boiling in SDS-PAGE sample 
buffer. All samples were separated by SDS-PAGE and transferred to PVDF membranes 
for analysis by standard colorometric immuno-detection with our Mouse 3 anti-p561ck 
polyclonal ascites fluid as our primary antibody and alkaline phosphatase conjugated 
secondary antibodies. Culture density was used to determine equal loading on gels. 
30 
Pulse-chase analysis 
Pulse-chase analysis of p561ck in GA treated Jurkat T cells was done in 
collaboration with Dr. Steve Hartson (Oklahoma State University, Stillwater, OK.). 
Sensitivity of newly synthesized p561ck in Jurkat T cells to GA was determined by 
pretreatment of cultures with 3.6 µM GA or DMSO (control) for 1 hour. Jurkat T cells 
were then starved for methionine and cysteine in the absence of GA by culturing in 
Met/Cys deficient RPMI 1640 media for 30 minutes at 37°C. Cellular proteins were then 
labeled by incubating cells in RPMI 1640 supplemented with [35S] Met/Cys for 20 
minutes (pulse). Pulse labeling was completed by removal of cells from media and 
resuspension and culture in RPMI 1640 supplemented with nonradioactive Met/Cys for 
the indicated chase times. Mature p561ck sensitivity to GA was also determined using 
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pulse-chase techniques. Cellular proteins in Jurkat T cells were radiolabeled for 40 
minutes followed by a 3-4 hour chase in non-radioactive Met/Cys supplemented RPMI 
1640 allowing [35S] labeled p561ck to mature. 3.6 µM GA or DMSO was then added 
directly to the culture and cells were incubated for the indicated chase times. To monitor 
[ 35S] labeled p561ck levels Jurkat T cells were lysed and clarified as described by Shaw et 
al. [131]. Protein-protein interactions in lysates were further disrupted, to increase 
immunoadsorption specificity, by adjusting lysates to a final concentration of 1 % SDS 
and 10 mM DTT and boiling for 5 minutes. Lysates were cooled and diluted. To reduce 
the affects of nonspecific binding of proteins to the immuno-matrix, lysates were . 
premixed with 10% Pansorbin followed by immuno-precipitation with anti-p561ck 
antibodies pre-bound to Pansorbin. Immuno-matrix was washed four times with lysis 
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buffer supplemented with 0.3% SDS/3 mM DTI and eluted with SDS-PAGE sample 
buffer. Immuno-precipitated proteins were separated by SDS-PAGE and transferred to 
PVDF membranes and analyzed by autoradiography for detection of [35S] labeled p561ck. 
Levels of [35S]p561ck were measured by computer densitometry of bands on the 
autoradiogram. p561ck immunoprecipitations from GA and DMSO treated Jurkat T cell 
lysates were also assayed for kinase activity. Activity was measured by quantification of 
the auto-phosphorylated [32P]p561ck band using computer densitometry on 
autoradiograms. 
p561ck ubiquitination analysis 
Since treatment of Jurkat T cells with clasto-lactacystin ~-lactone (CL) was 
determined to recruit p561ck to a RIP A/detergent insoluble fraction, a different lysis 
method was used to analyze these samples. Jurkat T cells were treated with GA and/or 
CL for the indicated times and harvested by a single centrifugation at 400 x g followed by 
a 5 minute boiling lysis in TNES buffer (50 mM Tris-HCl pH 7.4, 1 % NP-40, 2 mM 
EDTA, 100 mM NaCl, 2% SDS, 10 mM N-ethyl-maleimide (NEM), 1 mM Na3V04, 20 
µglml leupeptin, and 200 µg!L aprotinin). Cellular DNA was sheared using a 21 gauge 
needle and lysates were cooled and clarified twice by centrifugation. Some samples were 
then prepared for separation by SDS-PAGE and others were immunoprecipitated with 
Bum's anti-p561ck IgG or nonimmune IgG antibodies prebound to prewashed fast flow 
protein-G Sepharose (Amersham Bioscience). Immunopellets were washed four times in 
a modified TNES containing 0.2% SDS. Proteins were eluted by boiling in SDS-PAGE 
sample buffer. Samples were separated by SDS-PAGE and electro-blotted to nitro-
32 
cellulose membranes for immunodetection with anti- p561ck and anti-ubiquitin antibodies. 
Anti-ubiquitin antibodies are not very efficient at western blotting and require the 
membranes to be autoclaved for 15 minutes supposedly to make the epitope more 
accessible to the antibody. After autoclaving normal western-blotting protocols were 
followed. 
Results 
GA treatment is cytotoxic and inhibits growth of Jurkat T cell cultures 
Previous studies of the effects of GA and Herbimycin A on T cells have not 
examined the cytotoxicity or growth inhibition of these agents in any great detail. To 
determine the effects of GA treatment on the cultured Jurkat T cell line, cultures were 
treated with increasing concentrations of GA for 20 hours. Figure 2A shows the 
concentration dependent effect of GA on cell growth and viability after 20 hours of 
continuous treatment. At 900 nM GA there was only a 10 % loss of viability but growth 
was inhibited by almost 50 %. A 10 fold increase in GA concentration caused about a 30 
% loss in culture viability with little additional effect on growth inhibition. Even the live 
cells, cells that excluded trypan blue, had a different morphology appearing more 
crinkled and less rounded suggesting that they may be undergoing apoptosis. Recovery of 
these cells was greatly compromised by washing so washing steps were omitted in 
subsequent experiments. To determine how rapidly these effects occurred an intermediate 
time point was included in the dose curve (figure 2B). As can be seen at 8 hours, little 
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Figure 2. Growth and Viability of GA Treated Jurkat T Cells. 
(A) E6-1 Jurkat T cells were cultured in media in the presence or absence of the 
indicated concentrations of GA (900 and 9000 nM) or DMSO (vehicle control) 
for 20 hours. Cells were harvested as a pellet in an eppendorf tube by 
centrifugation at 400 x g for 10 minutes and counted on a mm2 hemocytometer 
grid using a microscope at lOx magnification. Bars on the graph represent the 
average % viability (calculated as# of cells unstained by the vital dye divided 
by the total # of cells counted for each culture multiplied by 100) and % growth 
(calculated as the# of cells in a given condition divided by the# of cells for the 
DMSO control multiplied by 100) in 13 experiments (5 replicate counts each). 
Error bars are the calculated standard deviations for each condition. P values for 
growth and viability at both 900 and 9000 nM of GA were< 0.01. (B) Jurkat T 
cells were cultured in media in the presence or absence of the indicated 
concentrations of GA (0, DMSO, 400, 900, 4000, and 9000 nM) and for the 
indicated times (8 and 20 hours). Both time points are graphed together to 
emphasize the difference in growth between cultures over time. Cells were 
harvested and counted and stained as in panel A. Standard deviations were 
calculated from 5 replicate counts and are presented as error bars. P values for 
growth at 20 hours and all treatment conditions were <0.01. P values for 
viability at 20 hours and 400 and 900 nM of GA were <0.05 and for 4000 and 
9000 nM of GA were <0.01. P values are given textually and are not displayed 
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effect on culture density was observed, and no effect on viability of the cultures was 
apparent even at the highest concentration, 9 µM. However, when the culture time was 
extended to 20 hours growth was inhibited and viability was lost in a concentration 
dependent manner. Inhibition of growth was apparent at the lowest GA concentration 
tested, 400 nM, and viability of cultures was compromised by 70% at the 9000nM. 
GA has different effects on the viability of resting and activated splenic T cells 
Jurkat T cells are a human leukemia T cell line that is used as a T cell model 
system for studying T cell receptor signal transduction. They express all of the 
components of the TCR and are able to be activated through the TCR to produce the 
stimulatory cytokine IL-2 [129, 132]. However, the cultured transformed Jurkat cell line 
may react differently to GA treatment than do non-transformed T cells in the body. In 
order to determine whether Jurkat T cells respond similarly to GA, as would T cells from 
a primary source, mononuclear cells were isolated and cultured from the spleen of DBA 
mice. Mature T cells in organisms not mounting an immune response are mostly 
quiescent and so some of the isolated T cells were pre-activated with IL-2 and Con A, 
mitogens that activate T cell proliferation [133]. Cells were cultured with or without GA 
for 15-18 hours and then counted and assayed for viability. Splenic mononuclear cells 
are a primary cell that can be cultured but are not as stable in culture as transformed cell 
lines such as Jurkat T cells, therefore they show a higher background mortality in culture. 
For this reason shorter treatment times were used for these cultures. At 15 hours no 
significant effect on culture viability was observed for resting T cells (Figure 3A). Upon 
longer treatment (24-72 hours), however, a concentration dependent reduction in culture 
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viability was detected along with a general decrease in viability for all cultures (data not 
shown). Activated T cell cultures showed an enhanced mortality upon exposure to GA 
(Figure 3A). Geldanamycin also inhibited T cell proliferation, as measured by 
[3H]thymidine incorporation in response to mitogen pretreatment, in a concentration 
dependent manner (Figure 3B). Similar work showed that pretreatment with Hsp90 
inhibitors blocked both TCR-mediated phosphorylation and CD28.:.mediated T cell 
activation [126, 134]. These results indicate that Hsp90 function is necessary to initiate 
and maintain T cell activation in the presence of mitogens. 
T cells also respond to activation through the TCR and other receptors by 
producing cytokines necessary to stimulate growth of other immune cells. This response 
was inhibited in human peripheral T cells by GA and herbimycin A, another 
benzoquinone ansamycin [126, 134]. When splenic T cells were pretreated with GA and 
then stimulated with anti-TCR antibodies (anti-CD3) IL-2 production was inhibited by 
96%. Similarly, production of the IL-2 receptor in response to stimulation with anti-
CD28 antibodies was inhibited by 40% when cells were pretreated with GA. These 
results indicate that both proliferation arid cytokine production in response to T cell 
activation were inhibited by GA treatment. Activated T cells also appear to be more 
vulnerable to GA cytotoxicity. 
Jurkat T cells have the ability to proliferate in culture without being activated 
unlike resting/quiescent T cells. Jurkats are also more vulnerable to.GA cytotoxicity like 
the activated splenic monocytes; however, they do not produce IL-2 unless stimulated 
through the TCR or other cell surface receptors [129]. These results indicate that Jurkat T 
cells respond to GA treatment in a manner similar to mouse T cells isolated from the 
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Figure 3. Growth , Viability, and Stimulation of GA Treated Preactivated or Resting 
Splenic T Cells (Courtesy of Peter Yorgin). 
(A) Splenic mononuclear cells from DBA mice were isolated and cultured in the 
presence (activated) or absence (resting) of 10 U/ml IL-2 and 0.5 µg/ml Con A for 
72 hours. Cells were then treated with the indicated concentration of GA (0, 
DMSO, 17, 170, 1700nM) for 15-18 hours and then harvested for viability 
assessment as described for Jurkat T cells in Figure 1. Resting T cells were 
separated from the mixed population of isolated mononuclear cells as described in 
Materials and Methods using a flow cytometer. Bars represent % viability (as 
calculated above) and error bars represent standard deviations calculated from two 
experiment (6 replicates each). P values for viability of GA treated resting T cells 
were not significant at all concentrations when compared to untreated (0 nM) or 
DMSO controls. P values for activated T cells were <0.01 for all concentrations 
of GA when compared to untreated (0 nM) or DMSO controls. (B) Splenic 
mononuclear cells were isolated and cultured in the absence (resting) or presence 
(activated) of either 100 U/ml of IL-2, 0.5 µg/ml of Con A, or 10 U/ml of IL-2 
and 0.5 µg/ml of Con A for 72 hours. Cells were then treated with the indicated 
concentrations of GA (0, DMSO, 17, 170, 1700 nM) concomitant with 1 µCi of 
[3H]thymidine for 15 hour and then harvested as described in Materials and 
Methods by glass-filter binding. Liquid scintillation counting was used to 
determine the amount of [3H]thymidine incorporated by cells under the indicated 
conditions. Incorporation is reported as the stimulation index ( calculated as 
[ 3H]thymidine incorporated by cells under a given condition divided by the 
[ 3H]thymidine incorporated without stimulation (Resting)). Standard deviations 
calculated from three experiments are reported as error bars. P values for all 
concentrations of GA in IL-2 stimulated cells were <0.01. P values for 170 and 
1700 nM GA treatement of Con A stimulated cells were <0.01, and the p value 
for 17 nM GA with Con A was not significant. P values for 170 and 1700 nM GA 
treatment of IL-2 and Con A stimulated cells were <0.01, and the p value for 17 
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spleen and may represent an appropriate model to examine the biochemistry of GA in T 
cells. 
p561ck cellular tyrosine kinase depletion in response to GA 
Stimulation through the TCR starts a signal transduction cascade that ultimately 
leads to T cell activation. One of the earliest events in this pathway is the activation of 
p561ct, which in turn phosphorylates and activates other proteins necessary for signal 
propagation (reviewed in [135]). The importance of p561ck in TCR signal transduction is 
well established, and therefore can be used as a marker for the effects of GA in T cell 
biology [136, 137]. The p561ck and p5gn'n protein tyrosine kinases are depleted in human 
peripheral blood T cells pretreated with herbimycin A, correlating with a general loss in 
TCR-mediated tyrosine phosphorylation [126]. In order to compare the effects of GA on 
p561ck in resting, activated, and transformed T cells, and for comparison with previous 
studies, p561ck levels were monitored during treatment. Figure 4 shows western blots of 
p561ck from resting and activated splenic T cells, and from transformed Jurkat T cells 
(Figure 4 A, B, and C respectively). In resting splenic T cells p561cklevels were reduced 
by almost half (53.7 ± 23.1 %) when treated for 24 hours with 170 nM GA (Figure 4 A, 
lane 2 versus 4). This level dropped to 35.3 ± 14.1 % when the. GA concentration was 
raised 10 fold (Figure 4 lane 2 versus 5). At the same concentration of GA activated 
splenic T cells p561ck levels were reduced to background within 15 hours (Figure 4 B: lane 
3 and 5 compared to lanes 2 and 4 respectively), indicating the p561ck pool in these cells 
were more sensitive to GA treatment. In Jurkat T cells, p561ck levels also dropped in 
response to GA treatment but it took treatment times and concentrations of GA similar to 
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Figure 4. Geldanamycin Mediated Depletion of Cellular p561ck in Resting, Activated, and 
Jurkat T Cells. 
(A) (Courtesy of Peter Y orgin) Splenic mononuclear cells were isolated and 
cultured for 24 hours in the presence or absence of indicated concentrations of 
GA (0, DMSO, 17, 170, or 1700 nM represented in lanes 1-5 respectively). Cells 
were harvested and lysed by boiling in SOS-PAGE sample buffer. Samples were 
loaded on to an SOS-PAGE gel and separated by electrophoresis. Proteins were 
transferred from the gel to nitrocellulose membranes and immunoblotted with 
anti-p561ck antibodies (primary) and horseradish peroxidase conjugated secondary 
antibodies. Bands were visualized by autoradiography of chemiluminescent bands 
using the Luminol substrate. Detection of the actin protein in all samples was used 
to normalize the samples. Migration of size standards and p561ck is marked and 
labeled on the left side of the of the panel. (B) (Courtesy of Peter Yorgin) Splenic 
mononuclear cells were isolated and cultured with 100 U/ml IL-2 (activated lanes 
2 and 3), 0.5 mg/ml Con A (activated lanes 4 and 5), or just media (resting lane 1) 
for 24 hours prior to a 15 hour treatment with 1.7 µM GA (lanes 3 and 5), equal 
volume of DMSO (control lanes 2 and 4), or no treatment (lane 1). Samples were 
lysed and separated by electrophoresis as described for panel A and transferred to 
nitrocellulose membranes for immunoblotting with anti-p561ck antibodies. 
Molecular weight standards and p561ck migration is marked and labeled on the left 
side of the panel. (C) The transformed Jurkat T cell line (E6-l) as cultured in the 
presence (lanes 3-6 and lanes 8-11) or absence (equal volume of DMSO control-
lanes 2 and 7) of GA for 8 or 20 hours. Concentrations of GA used are 400 nM 
(lanes 3 and 8), 900 nM (lanes 4 and 9), 4000 nM (lanes 5 and 10), and 9000 nM 
(lanes 6 and 11). Cells were counted, viability assayed, and harvested as a pellet 
at indicated times by centrifugation at 400 x g for 10 minutes. Lysis was 
performed using volumes of cold RIPA buffer that normalized the cell density 
based on previous cell counts. Cell pellets were resuspended and rocked at 4 °C in 
cold RIPA buffer (see methods). Lysates were clarified by a 5 minute spin at 
14000 x g and 4 ° C and supernatants were mixed with fast flow G (ffG) 
immunoresin prebound to Santa Cruz Biological (SCB) anti-p561ck polyclonal 
antibodies or nonimmune IgG (nonspecific binding control lane 1) and prewashed 
before immunoprecipitation. Immunopellets were cleared from lysates and 
washed 4 times with cold RIPA buffer and eluted with SOS-PAGE sample buffer. 
Eluates were loaded on SOS-PAGE gels and separated by electrophoresis. 
Proteins were electroblotted on PVDF membranes and subjected to 
immunoblotting with OSU anti-Mouse 1 antibodies (primary) and alkaline 
phosphatase conjugated secondary anti-IgG's and visualized by colorometric 
staining. Migration of molecular weight markers and p561ck is marked and labeled 
on the left side of the panel. 
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those used with resting splenic T cells to achieve the same degree of loss (Figure 4C: 900 
nM GA at 8 and 20 hours; lanes 4 and 9). Once again these results indicate that Jurkat T 
cells respond to GA treatment in a manner similar to mouse T cells isolated from the 
spleen and represent an appropriate model to examine the biochemistry of GA in T cells. 
Since Jurkat T cells were much easier to culture and do not have the added complication 
of high mortality during long culture times, Jurkat T cells were used to study the 
biochemical mechanism by which GA induced p561ck depletion. 
GA has different effects on different pools of cellular p561ck 
GA-induced depletion of p561ck could occur through more than one mechanism. 
First GA could affect p561ck levels indirectly by affecting other Hsp90 processes that 
directly or indirectly affect p561ck. Previous work has identified and characterized the 
interaction between the p561ck and Hsp90 in vitro and in vivo [26, 46, 138, 139], and other 
Src-family kinases have been identified as Hsp90 clients [45, 140, 141], suggesting a 
direct effect of GA on p561ck depletion. If Hsp90 is necessary to maintain mature p561ck 
activity then inhibition of Hsp90 could generate an inactive, protease sensitive kinase. 
Alternatively, Hsp90 function may only be necessary for de nova folding and the mature 
p561ckmay be stable without Hsp90 maintenance. Depletion of cellular p561ck in this 
scenario would result from failure of newly synthesized Hsp90 dependent kinase to 
replace mature Hsp90 independent p561ck as it turns over by normal mechanisms. p561ck 
depletion would occur less rapidly by the second scenario. Our results show a fairly slow 
turnover of p561ck especially in the non-activated and Jurkat T cells, suggesting a failure 
to replace old kinase with new. In order to determine the mechanism of GA-mediated 
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depletion pulse chase analysis was used. Cells were pretreated with GA followed by 
pulse labeling newly synthesized p561ck with [35S]Met/Cys in the absence of GA and 
chased in the presence or absence of GA. A dramatic difference in half-life was observed 
(Figure 5 A). During a 120 minutes chase period ( only 80 minutes are shown) little 
[ 35S]Met/Cys labeled p561ck was lost in the DMSO vehicle control treated culture. In the 
GA treated culture -50% of the [35S]Met/Cys labeled p561ck was lost after 40 min of chase 
and was undetectable after 120 minutes of chase (data not shown). 
A similar experiment was done to determine the Hsp90 dependence of mature 
p561ck with different results. Cells were pulse labeled with [35S]Met/Cys in the absence of 
GA and chased for 3 hours also in the absence of GA. Cultures were then supplemented 
with DMSO or GA and aliquots were harvested every 6 hours over a 24 hour period. As 
can be seen in Figure 5 B, GA increased the rate of mature p561ck depletion by 
approximately 2 fold. In order to determine whether a loss of p561ck kinase activity 
preceded the loss of protein in GA treated cultures p561ck was immunoprecipitated and 
assayed for activity at 3 hours (Figure 5 C). Three hours was short enough that depletion 
of kinase was not significant but long enough to have inhibited cellular Hsp90 function. 
No significant difference in p561ck kinase activity was detected in the two cultures 
indicating mature kinase function was not compromised by loss of Hsp90 function. 
These results demonstrate that both newly synthesized and mature p561ck are 
depleted by GA treatment, with the newly synthesized p561ck apparently much more 
sensitive to GA than the mature. The depletion observed in previous figures is the result 
of both a rapid loss of newly synthesized p561ck combined with a slower loss of mature 
p561ck. Specifically, in Figure 4 C lane 5 the depletion seen at 8 hours of GA treatment is 
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Figure 5. Pulse-Chase Analysis of the Turnover of Newly Synthesized and Mature p561ck 
in GA Treated Jurkat T Cells (Courtesy of Steve Hartson). 
(A) Jurkat T cells were cultured for 1 hour in the presence of 3.6 µM GA or an 
equal volume of DMSO (vehicle control) before being transferred to media 
supplemented with [35S]Met/Cys for pulse radiolabeling in the absence of GA. 
Cultures were chased in media supplemented with nonradioactive Met/Cys for the 
indicated times (0-80 minutes) in the absence of GA. Cells were harvested and 
lysed in RIPA buffer and immunoprecipitated with anti-p561ck antibodies 
prebound to immuno-affinity matrix and prewashed. Immunopellets were washed 
and proteins eluted with SDS-PAGE sample buffer. Eluates were separated by 
SDS-PAGE and transferred to PVDF membranes and exposed to film to produce 
an autoradiogram. Migration of molecular weight markers is marked and labeled 
on the left side of the panel and mobility of p561ck is marked on the right side of 
the panel. (B) Jurkat T cells were pulse radiolabeled with [35S] Met/Cys in the 
absence of GA and chased (also in the absence of GA) for 3 hours in media 
supplemented with nonradioactive Met/Cys. Cells were cultured in the presence 
of 3.6 µM GA or an equal volume of DMSO for the indicated chase times (0-24 
hours) after which cells were harvested, lysed, and immunoprecipitated with anti-
p561ck antibodies. Immunopellets were analyzed as described for samples in panel 
A. (C) Jurkat T cells were cultured with 3.6 µM GA or an equal volume of 
DMSO for 3 hours. Cells were harvested and lysed in RIPA buffer and clarified 
lysates were immunoprecipitated with anti-p561ck antibodies. Immunopellets were 
washed thoroughly to remove any contaminating kinases. Equal aliquots of the 
immunoprecipitations were assayed in vitro for auto-kinase activity by incubating, 
for the indicated times, with kinase reaction mixtures at room temperature 
containing [y-32P]ATP. Kinase reaction mixtures were analyzed by SDS-PAGE 
and autoradiography of PVDF membranes to which [32P] labeled proteins were 
transferred. Phosphorimaging of autophosphorylated p561ck bands _was used to 
quantitate activity at the times indicated. Graph shows that auto-kinase activity is 
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both a failure to produce nascent p561ck necessary to replace old kinase combined with a 
more rapid turnover of mature p561ck. 
Proteasome inhibition and GA mediated depletion of p561ck 
Depletion of p561ck does not necessarily mean p561ck is degraded. Another 
possibility is that p561ck is relocated to a fraction of the cell that is insoluble under the 
lysis conditions used; however, since we monitored total cellular protein by solubilizing 
pellets in SDS sample buffer, loss is probably due to degradation. The cell has many 
different pathways for degrading cellular proteins. The two most active are the multi-
subunit proteasome protease complex, and the cellular organelle the lysosome. Due to 
previous reports that GA induced the degradation of some proteins by the proteasome 
[142] we hypothesized that the proteasome was also involved in GA mediated 
degradation of p561ck. In order to test the hypothesis that the GA mediated depletion of 
p561ck is through the proteasome, the highly specific proteasome inhibitors lactacystin or 
clasto-lactacystin 13-lactone were used in conjunction with 20 hours of GA treatment of 
Jurkat T cells, a time at which we were sure to see significant depletion of p561ck. Initially 
it appeared that clasto-lactacystin 13-lactone provided some protection against depletion of 
cellular p561ck (Figure 6 A lanes 3 versus 4). However, when the same experiment was 
repeated using a different method to lyse the cells it appeared that clasto-lactacystin 13-
lactone did not provide the previously seen protection against depletion of p561ck (Figure 
6 B lanes 3 and 4) and that clasto-lactacystin 13-lactone alone caused a depletion of 
cellular p561ck independent of GA treatment (Figure 6 B compare lanes 2 and 1). Upon 
analyzing the cell pellet after lysis in RIPA lysis buffer (containing SDS, Triton X-100, 
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and deoxycholate) a near total recruitment of p561ck to the detergent insoluble pellet 
occured upon treatment with proteasome inhibitor alone (Figure 6 C, lanes 2 and 4 ). The 
quantity of p561ck found in the detergent insoluble pellet was greatly increased over the 
normal amount of p561ck found in this pellet (Figure 6 C, lane 1). However GA alone did 
not cause a recruitment of p561ck to this fraction and in fact p561ck was mostly depleted 
from both fractions (Figure 6 B&C, lanes 3). 
Another characteristic of proteasome degradation is the ubiquitin modification 
that is necessary for recognition. Ubiquitination of proteasome substrates results in an 
upward mobility shift of protein bands due to the increased molecular weight conferred 
by ubiquitin, usually represented as several slower mobility/higher molecular weight 
bands due to multiple ubiquitin molecules being attached. In Figure 6 C lane 4 a faint 
band can be seen indicating a slower mobility form of p561ck that may represent the 
ubiquitin modification. 
The slower migrating band seen in Figure 6 C can be better seen in the clasto-
lactacystin B-lactone treated Jurkat T cell lysate in figure 7 A lane 2 but is still 
represented as a minor population compared to p561ck. Figure 7 A also shows that the 
upper mobility band is immuno-precipitated in a specific manner and is specific to the 
clasto-lactacystin B-lactone treated culture. In an attempt to detect ubiquitinated p561ck 
duplicate samples of Jurkat T cell lysates were prepared and blotted with both anti-p561ck 
and anti-ubiquitin antibodies. Figure 7 B shows that clasto-lactacystin B-lactone 
treatment (lane3) results in a faint slower mobility band detected by anti-p561ck antibodies. 
Interestingly, in the DMSO treated lysate (Figure 7B, lane 1) no upper band can be seen; 
however, in the untreated lysate (Figure 7B, lane 5) an upper band is visible and an 
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Figure 6. Effects of GA and Clasto-lactacystin ~-Lactone Treatments on p561ck from 
Jurkat T Cells. 
(A) Jurkat T cells were cultured in the presence of 1.3 µM GA (lanes 3 and 4) 
and/or 10 µM clasto-lactacystin ~-lactone (lanes 2 and 4) for 20 hours. DMSO 
was used as a vehicle control in these experiments (lanes 1). Cells were counted, 
harvested, and lysed either by boiling in SDS-PAGE sample buffer for 5 minutes 
(whole cell lysate Panel A), or by rocking in cold RIPA at 4°C for 30 minutes. 
Lysis volumes were normalized to give a consistent concentration of cell lysate 
based on cell counting. RIPA lysates were clarified by centrifugation for 10 
minutes at 14000 x g at 4 °C. Cell lysis supematants where mixed with SDS-
PAGE sample buffer and boiled for 5 minutes and separated by SDS-PAGE 
(detergent soluble Panel B). RIPA detergent insoluble pellets were 
resuspended/dissolved by boiling for 5 minutes in SDS-PAGE sample buffer and 
separated by SDS-PAGE (detergent insoluble Panel C). Gels were electro-
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abundant lower mobility band which is very detectable by the anti-p561ck antibody is also 
observed. A comparison of the anti-p561ck blot and the anti-ubiquitin blot shows the upper 
mobility band may be ubiquitin-modified p561ck; however, the prominent band detected 
by anti-ubiquitin antibodies may migrate slightly slower than the upper band detected by 
the anti-p561ck antibodies (Figure 7B, lanes 5 and 6). The prominent band detected by 
anti-ubiquitin is seen in all of the treatments (Figure 7B, lanes 6-10). One reservation is 
that failure to detect the upperward mobility band by blotting with anti-p561ck may reflect 
epitope masking by the ubiquitin modification and therefore may not be a good indicator. 
The DMSO treated sample (Figure 7B, lane 6) appears less intense indicating that DMSO 
may affect the normal ubiquitination of this band. The abundant faster mobility band 
detected with anti-p561ck antibodies co-migrates with a band detected in the anti-ubiquitin 
blot (lanes 6 and 10). This band was not seen in the previous immunoprecipitation shown 
in figure 4C; however, different antibodies were used for immunoprecipitation. A 
commercially available antibody from Santa Cruz Biologicals was used in figure 4C and 
the rabbit anti- p561ck antibody from Paul Burns [26] was used in figure 7B and C. 
Differences in detection may represent differences in epitopes recognized by these 
antibodies. A general increase in ubiquitin-modified proteins can be seen in the clasto-
lactacystin f3-lactone treated lysates (Figure 7B, lanes 8 and 9). DMSO decreased the 
background of proteins detected by anti-ubiquitin even below that seen in the untreated 
lysate (Figure7B, lane 6 versus 10). Interestingly GA treatment does not appear to 
increase the background of proteins detected by anti-ubiquitin antibodies (compare lanes 
7 and 10). GA treatment also did not affect the intensity of the upper mobility band 
detected by anti-p561ck relative to the DMSO control (compare lanes 2 and 1). This 
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indicates that GA did not affect the quantity of this band or the abundance of the 
prominent band detected by anti-ubiquitin antibody or the background of ubiquitinated 
proteins. The identity of the upper and lower bands detected by anti-p561ck antibodies are 
still unknown although they are probably p561ck that has undergone some post-
translational modification or degradation whether it is ubiquitin dependent or not. 
In order to identify both the upper and lower bands detected in the anti-p561ck 
western blot, lysates from Jurkat T cells treated with GA and/or clasto-lactacystin ~-
lactone were immunoprecipitated with anti-p561ck antibodies (Figure 7C). A band with 
similar mobility as the prominent band detected by anti-ubiquitin in Figure 7B is 
immuno-specifically precipitated by anti-p561ck antibodies (Figure 7C, lanes 1-4). The 
abundance of this band is unaffected by GA treatment (compare lanes 2 and 4). However, 
upon clasto-lactacystin ~-lactone treatment the abundance of this band does not increase, 
only the nonspecific binding to the immunomatrix increases (Figure 7C, lanes 5 and 6). 
Treatment with both GA and clasto-lactacystin ~-lactone reduces the nonspecific binding 
to an extent (Figure 7C, lane 7) but also seems to decrease the quantity in the immune 
lane (Figure 7C, lane 8 vs lanes 2 and 4). Anti-p561ck antibodies, however, do not detect 
the same band detected by the anti-ubiquitin blot even though it is specific to anti-p561ck 
immunoprecipitations. Anti-p561ck antibodies do detect some faint upper mobility bands 
although they do not co-migrate with any of the bands detected by the anti-ubiquitin 
antibodies (Figure 7C lane 9). A band of similar mobility to the faster mobility band 
previously seen only in untreated lysates (Figure 7B lane 5) is detected in the GA/clasto-
lactacystin ~-lactone lane although at a reduced quantity from that seen in figure 7B, and 
it is not detected in the anti-ubiquitin blot, indicating it probably is not the same band. 
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Figure 7. Ubiquitination Analysis of p561ck from GA and/or Clasto-Lactacystin B-Lactone 
Treated Jurkat T Cells. 
(A) Jurkat T cells were treated with (lane 2) or without (lane 3) 10 µM clasto-
lactacystin or equal volume of DMSO (lane 1) for 6 hours. Cells were counted 
and lysed by boiling in TNES (2% SOS and 10 mM NEM) buffer. Lysis volumes 
were normalized to give equal lysate concentration based on cell counting. DNA 
was sheared by passing lysates through a needle. Lysates were clarified twice by 
centrifugation before mixing for 3 hours with Bum's rabbit anti-p561ck polyclonal 
antibodies, which were prebound and washed on fast flow G-sepharose. 
Immunopellets were washed 4 times with TNES (0.2% SDS only). Proteins were 
eluted by boiling immunepellets in SOS-PAGE sample buffer and loaded and 
separated by SOS-PAGE. Proteins were then electro-blotted from gels to PVDF 
membranes and immunoblotted with an OSU Mouse 1 and 3 anti-p561ck 
polyclonal ascites cocktail. Mobility ofrmolecular weight markers and p561ck are 
marked on the left side of the panel. Lane 3 shows immunoprecipitation of 
untreated lysate with rabbit nonimmune antibodies as a control for nonspecific 
binding of proteins to immunomatrix. (B) Jurkat T cells were treated with 1.3 µM 
GA (lanes 2 and 7), 10 µM clasto-lactacystin B-lactone (lanes 3 and 8), both 
(lanes 4 and 9), equal volume of DMSO (lanes 1 and 6), or media (lanes 5 and 10) 
for 6 hours. Cells were lysed by boiling in TNES and duplicate samples were 
loaded on to SOS-PAGE gels for separation. Proteins were electro-blotted on to 
nitrocellulose membranes and immunoblotted with either anti-p561ck (lanes 1-5) or 
anti-ubiquitin (lanes 6-10) antibodies. Membrane to be anti-ubiquitin blotted was 
autoclaved submerged in water for 15 minutes prior to normal immunoblotting. 
Mobility of molecular weight markers is labeled on the left side of the panel. 
Mobility of p561ck is marked on the right side of the panel. (C) Jurkat T cells were 
treated with 1.3 µM GA (lanes 3 and 4), 10 µM clasto-lactacystin B-lactone (lanes 
5 and 6), both (lanes 7-9), or equal volume of DMSO (lanes 1 and 2) for 6 hours. 
Cells were lysed by boiling in TNES and DNA was sheared as described for Panel 
A. Samples were immunoprecipitated with anti-p561ck (I-immune: lanes 2, 4, 6, 8, 
and 9) or nonimmune antibodies (NI: lanes 1, 3, 5, and 7). Proteins eluted from 
immunopellets were separated by SOS-PAGE and proteins were electroblotted 
from gels to nitrocellulose membranes. Membranes were immunoblotted with 
anti-ubiquitin or anti-p561ck antibodies. Duplicate samples of GA and clasto-
lactacystin B-lactone treated cell lysate were loaded side by side (lanes 8 and 9) in 
order to facilitate lining up bands detected by either the anti-ubiquitin immunoblot 
(lanes 1-8) or anti-p561ck immunoblot that co-migrate. Mobility of molecular 
weight standards is labeled on the left of the panel and mobility of p561ck is labeled 
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Once again GA does not increase the levels of the prominent immune-specific band 
detected in the anti-ubiquitin blot and in fact reduces its levels somewhat in the GA and 
clasto-lactacystin f3-lactone treated samples. This suggests that the levels of this protein, 
whether ubiquitinated p561ck or not, is unaffected by GA treatment. If the prominent band 
detected by anti-ubiquitin blotting of anti-p561ck immunoprecipitates is p561ck then 
ubiquitination of p561ck is not induced by GA treatment as has been reported for other 
proteins [ 117-120]. Rather it appears that if anything p561ck undergoes ubiquitination 
normally, which may even be in an Hsp90 dependent manner and that GA treatment 
alters this mechanism. Further consideration of p561ck ubiquitination and degradation in 
the context of recent publications follows in the discussion. 
Lysosomal inhibition affects GA mediated depletion ofp561ck 
Due to the ambiguous nature of the results from experiments attempting to 
identify the role of the proteasome in GA mediated depletion of p561ck an alternative 
proteolytic pathway was examined. The lysosome is a membrane bound organelle 
containing several proteases active at acidic pH and is involved in the degradation of 
cellular proteins under both normal and abnormal conditions. The lysosome and the 
proteasome pathways for protein degradation represent two of the major pathways for 
metabolism of proteins in the cell. In order to test the hypothesis that the GA mediated 
degradation of p561ck is through the lysosome, the V-ATPase inhibitor bafilomycin A was 
used to rescue p561ck. V-ATPases regulates the internal pH of the lysosome organelle and 
when inhibited the pH rises, subsequently inactivating lysosmal proteases. Figure 8 
shows that bafilomycin A provided some protection against GA mediated degradation 
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Figure 8. Effect of Lactcystin and Bafilomycin A on GA Mediated Depletion of p561ck in 
Jurkat T Cells (Courtesy of Peter Yorgin). 
Jurkat T cells were cultured with media (lane 1), 2 µM bafilomycin A (lane 2) or 
10 µM lactacystin (lane 3) for three hours or with media (lane 4), 1 µM 
bafilomycin A (lane 5), 1.7 µM GA (lane 6), 10 µM lactacystin (lane 7), 2 µM 
bafilomycin A and 1.7 µM GA (lane 8), or 10 µM lactacystin and 1.7 µM GA 
(lane 9) for 15 hours. Cells were lysed in cold RIP A buffer and separated by SDS-
p AGE. Proteins were transferred to nitrocellulose membranes, which were probed 
with anti-p561ck antibodies. Mobility of molecular weight standards is labeled on 
the left of the panel and p561ck mobility is labeled on the right of the panel. 
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and that bafilomycin A did not recruit p561ck to the detergent insoluble pellet (compare 
lanes 6 and 8). This data suggests that GA mediates p561ck depletion in Jurkat T cells by 
inducing degradation through the lysosome. The inability to detect an increase in 
ubiquitin-modified p561ck in GA treated Jurkat T cell lysates suggests that ubiquitination 
of p561ck is at least not stimulated by GA. 
Discussion 
The reported Hsp90 dependent substrates and their known roles in cell cycle 
progression, proliferation, and signal transduction have made Hsp90 a target for cancer 
therapy. Currently the selective cytotoxic effects of GA are being studied for use in 
cancer therapy (reviewed in [125]). The work presented here furthers our understanding 
of the effects of Hsp90 inhibition on various cell populations. Comparison of the 
cytostatic and cytotoxic effects of GA on the resting splenic mononuclear cells and both 
the activated splenic mononuclear cells and the transformed Jurkat T cell line show that 
the latter populations are more sensitive to GA. This suggests that proliferating cells are 
more sensitive to GA cytotoxicity than nonproliferating cells, although, GA is also toxic 
to resting splenic mononuclear cells upon longer treatment. Chemotherapeutic agents are 
often toxic to nontargeted cells and an unfortunate side effect of treatment is toxicity to 
protective proliferating immune cells. Our results also show that GA treatment inhibited 
the effects of T cell activation through the antigen receptor (TCR), CD28, IL-2R/CD25, 
and through the less specific mitogenic stimulation of Con A, thus potentially affecting 
the ability to mount an immune response during treatment. An account published during 
the preparation of this text on the effects of GA treatment on activation of peripheral T 
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lymphocytes through the CD28 receptor reported similar results on T cell proliferation, 
and IL-2 and IL-2R production [134]. These results suggest thatHsp90 function is 
necessary for several signal transduction pathways in T cells. 
To monitor GA affects at the molecular level the known T cell specific Hsp90 
substrate p561ck was studied. The cytotoxic effects of GA treatment are probably only 
partly incurred by the effects seen on p561c\ however; the effects on signal transduction 
through the receptors listed above are very directly related to p561ck since all use p561ck for 
signaling. Results presented here show that GA treatment of resting and activated splenic 
mononuclear cells, and Jurkat T cells results in a general depletion of cellular p561ck 
levels. Interestingly, GA mediated depletion of the p561ck in activated splenic 
mononuclear cells is more rapid than in resting splenic mononuclear cells, which 
correlates with the cytotoxicity. Geldanamycin mediated depletion of p561ck in Jurkat T 
cells occurs on a time scale similar to the depletion of p561ck in resting mononuclear cells; 
however, it can be accelerated at higher concentration of GA. Our results indicate p561ck 
depletion has two causes: 1) a dramatic compromise and total degradation of newly 
synthesized p561ck pools that normally replace mature p561ck upon degradation, and 2) a 2-
fold increase in the rate of turnover of mature p561c\ with accelerated loss being most 
apparent at later treatment times. The first is much more rapid and probably contributes 
more quantitatively to the depletion seen in our studies than the second mechanism. The 
second mechanism is slower and does not represent a large contribution to the overall 
loss of p561ck in GA treated cells, and may be an indirect effect of long term treatment. 
However, the reported effects on both pools of p561ck show that both pools are dependent 
on Hsp90 to varying degrees. Recent reports supporting this observation and data 
59 
presented in Chapter 4 show that in vitro as well as in vivo newly synthesized p561ck 
depends on Hsp90 to mature to a stable form which is mostly Hsp90 independent [26, 27, 
138, 139]. The greater sensitivity of p561ck to GA mediated depletion seen in the activated 
splenic mononuclear cells may be an effect of activation of the kinase. T cell activation 
through receptors activates the protein tyrosine kinase activity of p561ck. Activated Src-
family tyrosine kinases, especially the mutant transforming variety, are more reliant on 
Hsp90 function [27, 143], which agrees with the more rapid degradation of p561ck in GA 
treated activated splenic mononuclear cells. The resting splenic mononuclear cells and 
the Jurkat T cells in which p561ck has not been activated show a slower rate of GA 
mediated depletion. Alternatively, activated splenic mononuclear cells may turnover 
activated p561ck more rapidly independent of GA treatment. The effect of GA treatment 
may be to inhibit the replenishment of p561ck by increasing the degradation of newly 
synthesized kinase. Whether the increased rate of depletion of p561ck in activated T cells is 
due to an increase in the rate of turnover of mature activated kinase or an inability to 
replenish mature active kinase stores will require further study. 
Due to previous reports that Hsp90 inhibition stimulated the degradation of some 
Hsp90 clients via the proteasome we tested the hypothesis that GA mediated a similar 
degradation of p561ck. Initial inquiry indicated that proteasome inhibition protected p561ck 
from GA mediated degradation. A more thorough examination showed that the 
proteasome inhibitor had effects on p561ck independent of GA treatment, making our 
initial conclusion questionable. The complex effect of the proteasome inhibitor on 
recruitment of p561ck to a RIP A detergent insoluble fraction independent of GA treatment 
indicated the protective effect of the inhibitor was unrelated to GA treatment. These 
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results along with reports of other proteins being recruited to detergent insoluble fractions 
upon proteasome inhibition require careful interpretation of such experimental results 
[120, 144]. In order to further characterize the potential of proteasome degradation of 
p561ck in GA treated T cells anti-ubiquitin western blots were conducted on both whole 
cell lysates and anti-p561ck immunoprecipitations. In both samples ubiquitinated proteins 
were detected but it was unclear whether the protein bands detected by anti-ubiquitin 
antibodies were p561ck. It was clear, however, that GA did not increase the quantity of the 
ubiquitin specific bands even when the proteasome was inhibited indicating that GA 
mediated degradation of p561ck was not catalyzed by the proteasome, a result decidedly 
contrary to a mechanism in the literature that GA automatically targets client proteins to 
the proteasome [125, 145]. The fact that an immune-specific band precipitated by anti-
p561ck antibodies was detected by the anti-ubiquitin western blot suggests that p561ck may 
be ubiquitinated and degraded by the proteasome as part of its normal turnover. 
Subsequent reports of a physical association and ubiquitination of p561ck with both the 
E6AP and Cbl E3 ubiquitin ligases support this observation. In light of this new 
information our results suggest that the slight protection observed by treatment with 
clasto-lactacystin ~-lactone was due to inhibition of the normal turnover of p561ck and not 
GA mediated turnover. These reports also suggest that ubiquitin mediated degradation 
favored the active form of the Src family kinases, since constituitively active mutants 
were ubiquitinated and degraded more rapidly than the wild type kinase. Inactive kinase 
mutants were not ubiquitinated [146, 147]. The preferential degradation of activated 
p561ck is consistent with the observation that activated splenic mononuclear cells show an 
increase in the rate of p561ck depletion. 
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Since the ubiqutin-proteasome pathway did not appear to be involved in the 
observed GA mediated p561ck degradation, the common lysosomal pathway of protein 
degradation was the next focus due to its role in normal and abnormal protein degradation 
and its role in receptor endocytosis and degradation, a mechanism of possible importance 
for the receptor associated tyrosine kinase p561ck. The specific vacuolar-type H+-ATPase 
(V-ATPase) inhibitor bafilomycin A provided protection against GA mediated 
degradation of p561c\ a result consistent with lysosomal degradation. Bijlmakers et al. 
[139, 148] reported that Hsp90 activity was indirectly necessary for newly synthesized 
p561ck to associate with ER/Golgi compartment membranes and with the co-receptor CD4. 
Therefore, bafilomycin A protection against GA treatment may represent an alteration in 
newly synthesized p561ck trafficking through the ER/Golgi exocytic pathway. Bafilomycin 
A could also protect mature membrane associated p561ck from degradation if it is 
endocytosed along with the TCR on way to lysosomal receptor degradation. 
Alternatively, GA mediated degradation of p561ck could occur through more than one 
mechanism as reported for connexin 43 [149] and the epidermal growth factor receptor 
(ErbB-1). It is interesting to note that the Cbl ubiquitin ligase is reported to down regulate 
several signal transduction proteins, but not necessarily to the same degradation pathway. 
As mentioned, members of the non-receptor Src-kinase family interact with and are 
ubiquitinated by Cbl, and are then degraded by the proteasome. The epidermal growth 
factor receptor tyrosine kinase (ErbB-1), which in its nascent form is a reported Hsp90 
client [150], is also ubiquitinated by Cbl. The ubiquitinated receptor is then localized in 
endosome compartments. Both proteasome and lysosomal inhibitors were able to inhibit 
the degradation of the receptor, although the proteasome inhibitor showed more 
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protection [151, 152]. Another ErbB family member (ErbB-2/Her2), also an Hsp90 
client, is ubiquitinated, in response to GA treament, and localizes to endosomal 
membrane compartments, although its degradation is prevented only by proteasome 
inhibitors [153]. These results begin to suggest that degradation by the proteasome and 
lysosomal pathways are not as straightforward as previously thought, and that more than 
one pathway may work on one target. Finally, there is the possibility that a novel 
proteolytic pathway as described for a ZAP70 tyrosine kinase mutant [154] is at work. 
These results further our understanding of the effects of GA treatment on T cell 
biology, by extending characterizations to different populations of cultured cells. The 
enhanced sensitivity of proliferating T cells to GA cytotoxicity is shown relative to 
resting T cell populations and suggests potential usefulness in cancer and 
immunosuppresion therapies. Our study of the effects of GA on the p561ck kinase provides 
insight at the molecular level, showing that the newly synthesized p561ck is more sensitive 
to GA mediated degradation than the mature kinase. The effect on other Hsp90 clients 
would vary based on their Hsp90 dependence. The mechanism of GA mediated 
degradation is still unclear; however, our results do not support a GA induced ubiquitin-
mediated proteasome degradation as has been reported for other clients. These results 
provide a reference for using p561ck as a marker of GA pharmacological activity. 
Currently a derivative of GA is in Phase I clinical trials for cancer therapy and p561ck is 
being used as a marker in these studies ([125] and personal communication). Most of 
these results were published in the Journal of Immunology [127]. 
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CHAPTER3 
CO-TRANSLATIONAL ASSOCIATION OF MOLECULAR CHAPERONES WITH 
NASCENT POLYPEPTIDES CHAINS: A COMPARISON OF TWO 
EXPERIMENTAL TECHNIQUES 
Introduction 
De nova folding of some proteins begins while the elongating polypeptide is still 
bound to the ribosome. Evidence supporting co-translational folding is based on the study 
of model proteins by many methods including assays of function, resistance to protease 
digestion, proper disulfide bond formation, or recognition by conformation-dependent 
antibodies [l, 155-159]. Ribosome bound firefly luciferase is active but only when the C-
terminus is extended such that the last 12 amino acids, which are critical for activity 
[160], are no longer buried in the ribosomal tunnel [161]. Synthesis of a truncated firefly 
luciferase, lacking only the stop codon, produced an inactive full-length luciferase that 
remained bound to the ribosome. After release from the ribosome by puromycin, 
luciferase activity immediately appeared. When compared to renatured firefly luciferase, 
with a folding half-time of 14 minutes, the newly synthesized ribosome bound luciferase 
had significant functional structure, and supports a mechanism whereby folding begins 
co-translationally [162]. Similar experiments with C-terminally extended ribosome bound 
rhodanese produced an enzymatically active protein [163]. Significant structure can be 
found even in ribosome-bound polypeptides that are less than full length. Komar et al. 
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[164] reported that a ribosome-bound a-globin fragment as short as 86 amino acids was 
capable of specifically binding heme. These reports indicate a significant amount of de 
novo folding occurs during translation of these proteins, and suggests release from the 
ribosome is all that is necessary for completion of folding. The effect that release from 
the ribosome has on the overall three-dimensional structure of different proteins may 
depend on the importance of the C-terminal 30-40 amino acids, held in the ribosomal 
tunnel, to the final structure. 
In the cell, newly synthesized polypeptides emerge from the ribosome into a 
complex crowded environment where nonproductive interactions with self, other 
proteins, or other biomolecules are very likely. Some initial folding events may be 
facilitated by the ribosome itself (reviewed in [165]). However, cells have developed a 
specific group of proteins called molecular chaperones that facilitate the folding of some 
proteins by preventing or reversing improper interactions between protein surf aces that 
are necessary for a functional three-dimensional structure [6]. There are many families of 
molecular chaperones and their role in protein folding in the cell is the focus of much 
current research (reviewed in [7]). Recent reports suggest that the Hsp70 and Hsp60 
(chaperonin) families are the major contributors to chaperone mediated de novo folding 
[49, 50, 166]. Estimates of 15-20% of newly synthesized cytosolic polypeptides in HeLa 
and BHK (Baby Hampster Kidney) cells co-precipitated with Hsp70 [49, 50] and 9-15% 
of newly synthesized polypeptides in BHK cells co-precipitated with TRiC (the cytosolic 
chaperonin TCP-I ring complex or CCT) [50]. This means an estimated 65% of newly 
synthesized cytosolic proteins fold without Hsp70 or TRiC assistance. Some of these 
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proteins may fold to a native state independently; however, other proteins may need the 
aid of other cytosolic chaperones. 
Eggers et al. [ 49] restricted their study to translating polypeptides by using 
puromycin to release incomplete polypeptides from the ribosome and then 
immunoprecipitating with either puromycin specific or chaperone specific antibodies. 
Chaperone interactions were detected by western blotting proteins that co-
immunoprecipitated with the puromycyl polypeptides or co-immunoprecipitation of 
radiolabeled puromycyl polypeptides by specific chaperone antibodies. Similar 
techniques have been used to look at co-translational interaction of chaperones with 
model proteins such as firefly luciferase, actin, and rhodanese [158, 167-169]. Most of 
these techniques focus on associations with the puromycin released fragments, which 
may represent misfolded polypeptides or folding mutants that may never achieve an 
independent three-dimensional structure due to incomplete folding information. The 
significance of results from such experimental techniques should be considered carefully 
[170]. An alternative technique used by Eggers et al. [49] to detect co-translational 
chaperone interactions allowed a more straightforward interpretation. Newly synthesized 
radiolabeled polypeptides were cross-linked to associated proteins in.vivo prior to lysis 
and immunoprecipitation by chaperone specific antibodies. This confirmed the Hsp70 
and Hsp60 co-translational interaction with nascent polypeptides and implicated Hsp90 
as a co-translational chaperone. Hsp90 antibodies co-precipitated a distinct, but less 
abundant population of nascent polypeptides, which agrees with a model of Hsp90 
operating on a restricted clientele [ 171]. Our lab has reported the co-translational 
interaction of Hsp90 machinery with a protein that is folded and regulated by Hsp90 
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activity, the heme-regulated eIF2a. kinase (HR.I). The significance of such interactions is 
underscored by studies showing the failure of newly synthesized HR.I to achieve heme-
regulated kinase activity in the absence of Hsp90 function [100, 172]. Here we report the 
co-translational chaperone interactions of three Hsp90 substrate proteins in RRL and 
compare techniques for detection of co-translational chaperone interactions. 
Materials and Methods 
Plasmids 
The coding sequence for proteins to be synthesized in vitro were cloned into a 
modified pSP64T plasmid [173] as previously described [138, 172]. 
Polyribosome preparations 
Nuclease treated rabbit reticulocyte lysate (RRL) was programmed with pSP64T 
luciferase, pSP64T HR.I, or pSP64T Lek plasmid for coupled transcription and 
translation. Proteins were synthesized for 15 minutes at 30 °C as described by Hartson et 
al. [138]. Transcription was driven by the SP6 bacterial RNA polymerase promoter 
encoded in the pSP64T plasmid. Messenger RNA produced was translated in the 
presence of [35S] methionine by the protein synthesis machinery endogenous to 
reticulocyte lysate. Protein synthesis reactions were incubated for an additional 5 minutes 
at 30 °C in the presence or absence of 1 mM puromycin. After puromycin treatment 
protein synthesis reactions were diluted with 2 volumes of ice-cold buffer containing 20 
mM Tris-HCl (pH 7 .5), 25 mM KCl, and 2.5 mM magnesium acetate. Diluted reactions 
were layered on top of 15-40% sucrose gradients containing buffer and salt 
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concentrations consistent with the dilution buffer. Polyribosomes were separated by 
centrifugation for 4.5 hours at 40,000 rpm in an AH650 Sorval rotor. The supernatant of 
the polyribosome pellet were removed and ribosomal pellets were dissolved in 2X SDS 
sample buffer (125 mM Tris-HCl (pH 6.8), 10% SDS, 55 mg/ml dithiothreitol, 10% 
glycerol, 0.005% bromphenol blue [130]). Proteins present in the ribosomal pellets were 
separated by SDS-PAGE on 10% acrylamide gels. 
Immunoprecipitations 
Protein synthesis reactions not separated on sucrose gradients were 
immunoprecipitated with primary antibodies prebound to either goat anti-mouse IgG or 
goat anti-mouse IgM coupled agarose. The primary antibodies used were one of the 
following: monoclonal mouse anti-Hsp90 lgM (8D3), monoclonal mouse anti-Hsp70 IgG 
(BB70), polyclonal mouse anti-p50cdc37 IgG, mouse non-immune IgM (8D3 control), or 
mouse non-immune IgG (control for BB70 and anti-p5occtc37). Protein synthesis reactions 
were mixed with the immunoresin for 1 hour on ice. Immunoresins were washed five 
times with P150T (Pipes pH 7.0, 150mM NaCl, 0.5% Tween-20), and eluted by boiling 
in 2X SDS sample buffer for 5 minutes. Immunoprecipitated proteins were separated by 
SDS-PAGE on 10% acrylamide gels. 
Western Blot and Immunodetection 
10% SDS-PAGE gels were transferred to PVDF membrane and stained lightly 
with Coomassie blue to estimate the transfer efficiency. Membranes were dried and 
exposed to film to determine presence and pattern of radioactively labeled protein bands. 
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Membranes were cut according to molecular weight markers and probed with the 
appropriate chaperone antibodies: mouse polyclonal anti-Hsp90, mouse polyclonal anti-
Hsp70 (N27 StressGen), and mouse polyclonal anti-Cdc37 [46]. 
Results 
Hsp90 and p50cdc37 associate with ribosomes translating HR! mRNA 
The co-translational chaperone interactions of three proteins were chosen for 
study based on their different dependence on chaperone function. HRI, a known Hsp90-
dependent protein, was chosen as a positive control due documented co-translational 
interactions with Hsp90 and Hsc70 in reticulocyte lysate [100, 172]. Firefly luciferase 
was selected as a negative control since newly synthesized luciferase has been shown to 
fold independent of interactions with Hsp90. However, the Hsp90 chaperone machine 
interacts with and facilitates the refolding of denatured luciferase [174]. The Hsp90-
dependent Src-family tyrosine kinase p561c\ was chosen since its co-translational 
interactions with chaperones had not been characterized. These three proteins represent 
different types of Hsp90 substrates and a comparison of their Hsp90 and p50cdc37 co-
translational interactions may provide insight to these differences. 
In order to detect specific association of Hsp90 and p50cdc37 with ribosomes 
translating either firefly luciferase, HRI, or p561c\ nuclease treated RRL was programmed 
with plasmid DNA containing the cDNA sequence for each protein. After a short burst of 
translation half of the reaction was treated with puromycin to prematurely release nascent 
polypeptides from the ribosome without disrupting the rest of the ribosome complex. It 
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was important to release only the nascent polypeptide without disrupting the ribosome 
complex since we wanted to detect only proteins associating with the nascent chains 
while being translated, and not those associated with the ribosome complex. Members of 
the Hsp70 family of chaperones have been reported to associate with "vacant" ribosomes 
in a salt-sensitive manner and may play a role in protein synthesis [175, 176]. Even under 
low salt conditions we achieved good release of nascent polypeptides, as monitored by 
loss of [35S] labeled bands (Figure 9 B), with puromycin treatment. After a short 
puromycin treatment under protein synthesis conditions ribosomes from the protein 
synthesis reactions were separated by centrifugation through a sucrose gradient under 
conditions reported to pellet intact ribosomes (80S and greater) [100, 177-179]. The loss 
of nascent polypeptides in the HRI synthesis reactions (Figure 9, lanes 3 and 4) correlated 
with the loss of Hsp90 and p50cdc37 from the ribosomal pellet (Figure 9 A, lanes 3 and 4). 
Ribosome complexes were still intact based on three indicators: polyribosome profiles 
(not shown), Coomassie blue staining bands of resuspended pellets were unchanged by 
puromycin treatment (not shown), and the Hsp70 band on the western blot is still 
detected in the ribosomal pellet (Figure 9 A Hsp70 panel). The Hsp70 band in the 
ribosome pellet where nascent polypeptides have been released also indicates that rabbit 
Hsp70 interacted with vacant ribosomes as Pfund et al. [176] reported for yeast Ssb. Our 
result confirms Eggers et al. [49] assessment that Hsp90 interacts with some nascent 
polypeptides while still on the ribosome, although these interactions were not the same 
for all known Hsp90 clients since neither firefly luciferase nor p561ck showed evidence of 
co-translational interaction with Hsp90 or p50cdc37. 
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Figure 9. Chaperone Associations with Translating Ribosomes. 
Nuclease treated RRL was programmed with firefly luciferase (lanes 1 and 2), 
HR.I (lanes 3 and 4), or p561ck (lanes 5 and 6) cDNAs and allowed to synthesize 
protein for 15 minutes at 30 °C in the presence of [35S] methionine to radiolabel 
newly synthesized polypeptides. Protein synthesis reactions were then either 
treated (even lanes) or not treated (odd lanes) with 1 mM puromycin for 5 minutes 
at 30 °C to release nascent polypeptides from the translating ribosomes. 
Polyribosome complexes were separated from other RRL protein complexes by 
centrifugation through a 15 to 40% sucrose gradient as described in "Materials 
and methods". Components of the polyribosome complex were further separated 
by 10% SDS-PAGE and blotted to a PVDF membrane. The membrane was 
analyzed by (A) immunodetection with antibodies against Hsp70 (N27), Hsp90 
(polyclonal OSU), p50cdc37 (polyclonal OSU) and (B) exposure to film for 
detection of [35S] labeled nascent polypeptide. 2 µl of RRL (lane 7) were used as a 
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Co-precipitation of prematurely released nascent polypeptides by anti-Hsp90 antibodies 
An alternative technique used to detect co-translational interactions is 
immunoprecipitation or co-precipitation of prematurely released (by puromycin) nascent 
polypeptides using antibodies either for puromycin (to bring down the nascent 
polypeptides) or for specific chaperones of interest [ 49, 166, 167, 180]. Figure 10 is the 
autoradiogram of [35S] labeled nascent (puromycin released) polypeptides that co-
immunoprecipitated with Hsp90. Hsp90 co-immunoprecipitated specific bands, smaller 
than the full-length protein, for all three proteins, as seen in the immune lanes (Figure 10, 
lanes 2, 5, and 8). The 8D3 antibody co-precipitated a broad-range of HRI polypeptides 
(lane 5 vs 6). However, for p561ck the larger polypeptides seemed to be more highly 
represented in the co-immunoprecipitate (Figure 10, lanes 7-9). A select few luciferase 
polypeptides co-immunoprecipitated above background, although the background was 
especially high (Figure 10, lanes 1-3). Analysis of the autoradiogram indicated 
interaction of Hsp90 with some of the ribosome free incomplete products of each protein. 
Only the co-translational interaction of Hsp90 with HRI was detected by the ribosomal 
pellet technique (Figure 9). A comparison of the different techniques and reasons for the 
different results can be found in the "Discussion" section. 
Co-precipitation of prematurely released nascent polypeptides by anti-Hsp70 and anti-
p50Cdc37 antibodies 
Figure 11 is the autoradiogram of [35S] labeled nascent polypeptides that co-
immunoprecipitated with Hsp70 and p50cdc37_ Each protein had immune-specific bands, 
smaller than full-length, that co-precipitated with Hsp70 above background (Figure 11, 
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Figure 10. Co-Immunoprecipitation of Nascent Polypeptides with Monoclonal Anti-
Hsp90 Antibodies. 
Nuclease treated RRL was programmed with firefly luciferase (lanes 1-3), HRI 
(lanes 4-6), or p561ck (lanes 7-9) cDNAs and allowed to synthesize protein for 15 
minutes at 30 CC in the presence of [35S] methionine to radiolabel newly 
synthesized polypeptides. Protein synthesis reactions were then treated with 1 
mM puromycin for 5 minutes at 30 CC to release nascent polypeptides from the 
translating ribosomes. Equal aliquots of the protein synthesis reactions were 
mixed (as described in "Materials and methods") with goat anti-mouse IgM 
coupled agarose, which had been prebound with either anti-Hsp90 monoclonal 
IgM (I) or a non-immune IgM (NI) as a control. 2 µl of each protein synthesis 
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Figure 11. Co-Irnmunoprecipitation of Nascent Polypeptides with Anti-Hsp70 and Anti-
p50cdc37 Antibodies. 
Nuclease treated RRL was programmed with firefly luciferase (lanes 1-4), HRI 
(lanes 5-8), or p561ck (lanes 9-12) cDNAs and allowed to synthesize protein for 15 
minutes at 30 °C in the presence of [35S] methionine to radiolabel newly 
synthesized polypeptides. Protein synthesis reactions were then treated with 1 
mM puromycin for 5 minutes at 30 °C to release nascent polypeptides from the 
translating ribosomes. Equal aliquots of the protein synthesis reactions were 
mixed (as described in "Materials and methods") with goat anti-mouse IgG 
coupled agarose, which had been prebound with anti-Hsp70 monoclonal IgG 
(lanes 2, 6, and 10), anti-p50cdc37 IgG (lanes 3, 7, and 11) or a non-immune IgG 
(lanes 1, 5, and 9) as a control. 2 µ,l of each protein synthesis reaction were loaded 
(lanes 4, 8, and 12) to show the mixed population of polypeptides input in each 
irnmunoprecipitation. 
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lanes 2, 6, and 10). HRI and p561ck also had some nascent polypeptides that co-
precipitated with p50cdc37 (Figure 11, lanes 7 and 11); however, none of the luciferase 
nascent polypeptides co-precipitated with p50cdc37 above background (Figure 11, lanes 1 
and 3). As mentioned above for the Hsp90 immunoprecipitations, most of the co-
precipitating nascent polypeptides were the larger species. The p50cdc37 co-precipitation of 
p561ck and HRI mostly brought down polypeptides close to full length or full-length 
kinases (Figure 11, lanes 7 and 11), suggesting that p50cdc37 interaction requires more 
sequence or even a specific sequence or structure found close to the C-terminus of the 
protein. 
Chaperone/Domain interactions 
Since the two kinases being studied also showed differences in their co-
translational chaperone interactions possible reasons for the differences were sought. 
Previous work done in our laboratory suggested that p561ck interacted with Hsp90 and 
p50Cdc37 primarily through the kinase domain (Figure 12, lane 3 and [27]). However, HRI 
has multiple domains that interact with Hsp90 and Hsp70 (Figure 13, lane2 and 4). The 
domain organization of the proteins and the location of their interacting domains in 
relation to emergence from the ribosome might resolve these differences. The kinase 
domain of p561ck is at the C-terminus and is the last domain to emerge from the ribosome 
and therefore may not allow interaction until released from the ribosome. The heme 
binding domain (HBD; Figure 13, lane 4) is located at the N-terminus of HRI and would 
be exposed early allowing it to possibly interact with Hsp90, although there is no p50cdc37 
present. Also the two lobes of the HRI kinase domain are separated by a long insertion 
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Figure 12. Hsp90 and p50cdc37 Co-Immunoprecipitate with the Kinase Domain of p561ck. 
Nuclease treated RRL was programmed with histidine tagged full length p561ck 
(lane 2) or the histidine tagged protein tyrosine kinase catalytic domain (lane 3) 
cDNAs and allowed to synthesize protein for 20 minutes at 37 °C in the presence 
of [35S] methionine to radiolabel proteins. Protein synthesis reactions were then 
clarified and mixed with goat anti-mouse IgG coupled agarose, which had been 
prebound with anti-His monoclonal IgG (lanes 1-3). RRL with out template DNA 
was also immunoprecipitated with anti-His bound IgG coupled agarose as a 
control to determine the level of nonspecific binding of chaperones to the 
immunoresin (lane 1). 
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Figure 13. Hsp90 and p50cdc37 Co-Immunoprecipitate with the N-lobe of the HRI Kinase 
Domain (Courtesy of Jieya Shao). 
Nuclease treated RRL was programmed with the histidine tagged N-lobe of the 
HRI kinase domain (lanes 1 and 2) or the histidine tagged Heme-binding domain 
(HBD, lanes 3 and 4) cDNAs and allowed to synthesize protein for 20 minutes at 
30 °C in the presence of [35S] methionine to radiolabel proteins. Protein synthesis 
reactions were then clarified and mixed with goat anti-mouse IgG coupled 
agarose, which had been prebound with anti-His monoclonal IgG (lane 2 and 4) or 
with a control non-immune antibody (lanes 1 and 3). 
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sequence and may allow the N-terminal lobe (N-lobe Figure 13, lane 2) to protrude from 
the ribosome and interact Hsp90 and p50cdc37 before release. More consideration is given 
in the discussion. 
Discussion 
The co-translational interaction of Hsp90 and p50cdc37 with the ribosome bound 
HRI kinase (Figure 9) indicates that Hsp90 and p50cdc37 play a role in folding some 
nascent polypeptides while still on the ribosome. This early interaction with Hsp90 and 
p50cdc37 supports the possibility that the Hsp90 chaperone cycle is taking place while the 
kinase is still being translated. In the traditional Hsp90 cycle model for steroid hormone 
receptors proteins are initially recognized and folded by Hsp70, and cofactors, then 
passed to Hsp90, and cofactors, via the dual interacting protein p60HoP (Hsp70/Hsp90 
Organizing Protein). The Hsp70-Hop-Hsp90 complex is referred to as the "intermediate" 
complex. Once Hsp70 and Hop dissociate, Hsp90 and various cofactors form what is 
called the "mature" or "late" complex (reviewed in [11]). p50cdc37 is one of the Hsp90 
cofactors that is traditionally reported in "mature" complexes ([ 46]). Since Hsp70 is also 
found in the ribosome pellets all of the components are at least present, therefore the 
Hsp70 may be passing the partially folded kinase to the Hsp90 machinery. Alternatively, 
the Hsp70 and Hsp90 chaperone machines may represent two alternative independent 
pathways. Either way this work indicates that Hsp90 folding is not restricted to post-
translational events. 
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The differences these substrates displayed toward Hsp90 machinery interaction 
(Figure 9) may be attributable to the concept of modular folding. This concept suggests 
that a protein's sequence is composed of modules that can fold and retain structure and 
function independently, in a manner similar to how they behave in the context of the full 
length protein. These modules have most of the same characteristics attributed to protein 
domains, although the definition of a protein domain has many uses that are not 
necessarily restricted by structural or functional considerations. For the purpose of 
folding they are referred to as independent folding units. Large proteins may have many 
domains each of which is thought to fold largely independent of other domains, although 
the interaction between domains is very important often representing strategies of 
regulation of function or complex formation. A comparison of the domain structure of 
these clients may help explain the differences in interactions. Hartson et al. [27] reported 
that the different domains of the p561ck kinase showed differences in dependence on 
Hsp90 activity to achieve function. When Hsp90 activity was inhibited during synthesis 
the SH2 domain, in the context of the full-length protein, folded to a functional structure 
capable of binding phosphotyrosine peptide. The kinase domain, however, was not active 
under the same conditions. This dependence is corroborated/supported by the interaction 
studies of the independently synthesized domains. The kinase domain of both HRI and 
p561ck is enough to co-immunoprecipitate Hsp90 and p50cdc37 (figures 12 and 13). In both 
proteins, the kinase domain is at the C-terminus representing the last complete domain to 
emerge from the ribosome, although both have their own unique C-terminal "tail" 
sequence. Hsp90 interaction with the kinase domain may be sterically hindered by the 
ribosome complex and may require release from the ribosome. The ribosome complex 
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can cover as many as 80 amino acids during polypeptide synthesis (reviewed in [165]). 
HR.I, however, has additional modules reported to interact with Hsp90 machinery. The N-
terminal Heme Binding Domain (HBO) interacts with Hsp90 machinery (Figure 13), and 
is the first domain to emerge from the ribosome and could explain why Hsp90 pellets 
specifically with the HR.I-ribosome complex. HRI also has an extended sequence (called 
the insertion sequence) that separates the N-terminal and C-terminal lobes of its kinase 
domain. This sequence has some Hsp70 interacting ability (unpublished observation), and 
may allow more of the kinase domain to be exposed for Hsp90 binding. Finally HR.I also 
has a longer C-terminal tail following its kinase domain than p561c\ which might function 
as described for the insertion sequence. One or more of these additional modules may 
allow Hsp90 machinery to bind HR.I while still on the ribosome, whereas p561ck appears 
to interact with Hsp90 machinery mostly through its C-terminal kinase domain. 
When results from the ribosome pellet technique (Figure 9) are compared with 
results from the co-immunoprecipitation technique (Figure 10 and 11) some differences 
stand out. Figure 10 shows that Hsp90 antibodies are able to co-precipitate nascent chains 
of firefly luciferase and p561ck even though Hsp90 is not detectable in the ribosome 
pellets. One explanation is the difference in sensitivity of the two techniques. Figure 9 
detection is based on the western blotting of a ribosomal pellet, which is less sensitive 
than detection of radioactive nascent polypeptides in the chaperone immunoprecipitations 
of Figures 10 and 11. The amounts of nascent polypeptides co-precipitated by Hsp90 
antibodies in the HRI and p561ck reactions are comparable, but Hsp90 is not detected in 
the ribosomal pellet of p561ck. The amount of co-precipitated luciferase nascent 
polypeptides is considerably less so Hsp90 and p50cdc37 may not be detectable in the 
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luciferase ribosomal pellet. Previous work in our lab indicates that luciferase does not 
require Hsp90 activity for de nova folding in RRL to become an active enzyme, but 
favors an Hsp90 pathway for refolding after being denatured [174]. 
Another possibility is that the co-immunoprecipitation of nascent incompletely 
synthesized luciferase and p561ck by the Hsp90 antibodies may be an artifact induced by 
the premature release of polypeptides from the ribosome. These polypeptides would be in 
various stages of folding, whether chaperone assisted or not, and represent various 
folding intermediates. Interactions with molecular chaperones would be expected since 
chaperones by nature of their cellular function have an affinity for unfolded polypeptides. 
A specific example of this is the role Hsp90 plays in re-folding denatured firefly 
luciferase. This is also supported by the observation that puromycin treatment of cultured 
chicken embryo cells stimulated a stress response inducing synthesis of Hsp70 among 
other stress proteins [166, 181] probably due to the release of mis-folded polypeptide 
chains. These interactions would not represent the true in vivo folding pathway of the de 
nova polypeptides emerging from the ribosomes. The interpretation of the co-
translational interaction between Hsp90 and luciferase is complicated further by the 
identification of more than one pathway for luciferase renaturation in RRL, although the 
Hsp90 dependent pathway is kinetically favored [182]. 
HRI is the only protein we can confidently say interacts with Hsp90 co-
translationaly since it is confirmed by both techniques, and since the interactions detected 
by the traditional co-immunoprecipitation method are questionable due to the known 
affinities of chaperones for unfolded potentially aggregating pools of proteins. However, 
HRI is the first example of a specific co-translational Hsp90 client indicating the 
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possibility of others as suggested by Eggers et al. [ 49] and the need to study other Hsp90 
co-translational interactions. Initial indications are that simply being an Hsp90 client does 
not qualify a protein for co-translational interactions. There is also the possibility that 
other proteins may be identified as Hsp90 clients while on the ribosome but not after co-
translational vectorial folding. 
The co-translation interaction of all three proteins with Hsp 70 is easier to 
interpret, and agrees with previous reports that Hsp70 interacts with ribosomes and many 
nascent polypeptides co-translationally [49, 158, 166, 167, 176]. Based on what is known 
about the Hsp70 recognition motif a co-translational interaction with all three is not 
surprising. Rudiger et al. [56] characterized the substrate-binding motif of the E. coli 
Hsp70 homologue DnaK by scanning peptide libraries generated from 37 biologically 
relevant proteins and found an Hsp70 binding motif every 36 to 84 amino acids by 
scanning. Most of these motifs would normally be buried in the hydrophobic core of the 
folded protein and not accessible; however, in the case of protein synthesis these sites 
would be exposed and available for Hsp70 binding and folding. The consensus substrate 
motif is better characterized for Hsp70 than for Hsp90. Our understanding of the Hsp90 
substrate-binding motif is very limited so no predictions about the prevalence of Hsp90 
binding sites can be made. However, Nathan et al. [171] reported little effect on total 
cellular protein de nova synthesis and folding upon of loss of Hsp90 function in yeast, but 
the effect on folding of specific known Hsp90 substrates was critical, indicating Hsp90 
does not play a critical role in folding of most cellular proteins. 
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CHAPTER4 
CHAPERONE INTERACTIONS WITH THE IMMATURE PROTEIN TYROSINE 
KINASE p561ck IN THE RRL MODEL SYSTEM 
Introduction 
Hsp90 machinery associates with and provides essential functions for several 
regulatory proteins including steroid hormone receptors and protein kinases (reviewed in 
chapter 1). Of these, the steroid receptor assembly pathway has been the most thoroughly 
characterized, and has generated the chaperone cycle model described in chapter 1. This 
work indicates that Hsp90 machinery provides essential reiterative maintenance folding 
for these receptor transcription factors, keeping them in a conformation capable of 
binding hormone. Hsp90 maintains prolonged, although dynamic, associations with these 
receptor complexes in the absence of hormone. For this reason receptor complexes can be 
isolated an characterized with less consideration for time than other complexes formed 
with proteins that only interact during de nova folding, such as p561ck. Some of the Hsp90 
client kinases also have prolonged maintenance interactions dependent on regulatory 
stimuli. In this way both steroid hormone receptors and client k:inases such as HRI are 
similar. Prior to maintenance these substrates also depend on Hsp90 for de nova folding, 
which is defined in different ways. For HRI, early folding intermediates interacting with 
Hsp90 machinery are not active and cannot be activated by normal stimuli (NEM and 
heme deficiency). Upon longer incubation of the complex, and inferred folding, Hsp90-
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associated HRI matures into a conformation that can be stimulated to become an active 
kinase [172]. 
Other Hsp90 clients appear to interact only during maturational de nova folding. 
Hsp90 associates with certain immature kinases, and the importance of this native 
association is implied from the effects of GA on stability of the immature protein's 
structure and activity [101, 117, 127, 139, 183]. A specific example of this is the p561ck 
kinase. Immature inactive p561ck synthesized in vitro interacts with Hsp90,and 
p561ck/Hsp90 hetrocomplexes are stable in the presence of high salt. However, in the 
presence of GA, p56lck/Hsp90 heterocomplexes are salt labile and the kinase is more 
sensitive to protease [27]. This also agrees with the results in chapter 2 showing a rapid 
degradation of newly synthesized p561ck in T cells treated with GA. 
A third group of Hsp90 clients can be defined by their dependence on Hsp90 as 
well. This group includes retrovirus-encoded oncogene products, such as v-src, v-fps, v-
yes, and v-fes, which were some of the earliest identified Hsp90 substrates [94]. Later 
these kinases were identified as mutant forms of cellular kinases, such as p6oc-src. Initially 
it was not clear whether the cellular kinases interacted with Hsp90. It is now being 
realized that the mutant kinases have a prolonged interaction with and continued 
maintenance dependence on Hsp90, in comparison to their cellular counter-parts [27, 
139]. This makes the Hsp90 interaction more readily detectable and may explain the 
initial confusion over Hsp90's role in the cellular "wild-type" kinase folding. 
As stated, the conditional maintenance folding of steroid receptors has been the 
most thoroughly characterized of Hsp90 clients; however, the de nova maturation of 
newly synthesized proteins, and how it relates to conditional and continued maintenance 
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is still poorly understood. One difference identified between two such Hsp90 clients is 
shown in chapter 3: the co-translational interactions of Hsp70, Hsp90, and p50cdc37 with 
HR.I, but not with p561ck. This work was done in RRL, which was also used for many of 
the characterization studies on steroid receptor assembly [31, 184-186]. Interactions with 
Hsp70, p60H0 P, p48HIP, Hsp90, FKBP51 and 52, Cyp40, and p23 were reported. The same 
components were associated with the recombinant Fes kinase and the Heat-shock 
transcription factor [45]. In order to study de novo maturational folding, a system for 
specifically generating nearly uniform pools of substrate protein in the presence of the 
chaperone machinery was needed. Since we also wanted to compare the results to the 
work done on steroid receptors in RRL, the in vitro coupled transcription-translation 
system of nuclease treated RRL was chosen. In addition in vitro translation allowed us to 
label our client with radioactive amino acids enabling very sensitive detection of client 
p561ck. Here we report the interactions of several chaperones and their co-chaperone 
partners specific to immature p561ck kinase. 
Materials and Methods 
Materials 
All cDNAs to be transcribed in vitro were cloned in to a modified pSP64T 
plasmid with an SP6 RNA polymerase promoter [173] as previously described [138]. 
Cloned cDNAs were: wild type p561c\ mutant p561ck in which the codon for the regulatory 
505 tyrosine was replaced with the codon for phenylalanine (F505); mutant p561ck in 
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which the codon for the active site 273 lysine was replaced with the codon for arginine 
(R273); catalytic domain in which only the sequence for the catalytic domain (Cat) of 
p561ck (residues 238-509); N-lobe containing only the sequence corresponding to the N-
terminal lobe of the catalytic domain of p561ck (residues 238-323); C-lobe containing only 
the sequence corresponding to the C-terminal lobe of the catalytic domain of p561ck 
(residues 316-509); HRI N-lobe containing only the sequence corresponding to the N-
terminal lobe of the catalytic domain of HRI (residues 154-231); and heme-binding 
domain (HBD) containing the sequence corresponding to the heme-binding domain of 
HRI (residues 1-153). 
L-[35S]-methionine and [y-32P]ATP were purchased from DuPont-NEN. 
Geldanamycin (GA) was provided by the Drug Synthesis and Chemistry Branch, 
Developmental Theraputics Program, Division of Cancer Treatment, National Cancer 
Institute and was prepared in DMSO (Sigma). Clofibric acid (CIA) was purchased from 
Sigma Chemical Co. (St. Louis, MO.) and was prepared in H20 by adjusting the pH with 
1 M KOH until only a little CIA was left undissolved. Sodium molybdate (Nai(Mo04)) 
was purchased from Sigma and was prepared as a 1 M stock in H20. Bovine serum 
albumin (BSA) and reduced carboxy-methylated-BSA (RCM-BSA) were purchased from 
Sigma and prepared in H20. Peptide-<!> (pep-<!> FYQLALT) was synthesized by the 
Sarkey's Biotechnology Research Laboratory (OSU) and purified by reverse-phase 
chromatography on a C18 column at the Molecular Biology Resource Facility 
(University of Oklahoma Health Sciences Center, UOHSC). Purity and concentration was 
analyzed by MALDI-mass spectroscopy and by quantitative amino acid analysis using~-
(thienyl)-DL-alanine as an internal standard. Purity was determined to be > 98%. Anti-
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penta His monoclonal antibodies were purchased from Qiagen. Antibodies for Hsp90, 
p5oct1c37, and p561ck were prepared by the Hybridoma Center for the Agricultural and 
Biological Sciences (OSU) as ascites fluid from mice immunized with recombinantly 
purified ~p50Cdc37 and H6p561c\ or with Hsp90 purified from RRL [46, 187]. Other 
antibodies used include: non-immune control mouse IgG from the MOPC-21 hybridoma 
(Sigma); N27 anti-Hsp70 mouse monoclonal IgG was purchased from StressGen; ECl 
anti-FKBP52 mouse monoclonal IgG was provided by Dr. Lee Faber [188]; anti-cyp40 
rabbit polyclonal antibody against the C-terminus was purchased from Affinity 
BioReagents (PA3-022); JJ3 and JJS anti-p23 mouse monoclonal antibodies were 
provided by Dr. David Toft [84]; goat anti-mouse IgG (for making immunoresin) and 
alkaline phosphatase conjugated goat anti-mouse and anti-rabbit IgG (secondary 
antibodies for western-blotting) were purchased from Jackson Immunoresearch 
Laboratories. Nitro blue tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP), and p-nitrophenyl-chloro-formamide activated agarose were purchased from 
Sigma Chemical Co. (St. Louis MO.). Goat anti-mouse IgG was coupled to agarose as 
previously described [189]. Enolase for p561ck kinase assays was purchased from Sigma 
and prepared as described by Cooper et al. [190] in enolase denaturation buffer (EDB-
50mM NaOAc/HOAc pH 3.3) and denatured at 30 °C for 5 minutes prior to mixing with 
kinase assay components. 
In vitro coupled transcription/translation in rabbit reticulocyte lysate 
pSP64T plasmids containing the indicated cDNAs were transcribed and translated 
in coupled reactions containing -70% (v/v) micrococcal nuclease treated rabbit 
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reticulocyte lysate (prepared as described in [191]). Other components and final 
concentrations are as follows: 7.8% (v/v) deionized distilled H20, 19.17% (v/v) TnT 
buffer [0.052 M creatine phosphate (Sigma), 0.0052 M dithiothreitol (Bio World), 0.0157 
M Mg(0Ac)2, 0.574 M KOAc (Sigma), 0.1 mM amino acid pool (-methionine), 4.177 
mM y-NTP pool (Boehringer Mannheim), 2.79 mM Tris-HCl (Sigma) to adjust pH to 
7.3]; 0.04 µg/µl pSP64T plasmid cDNA; 0.02% (v/v) SP6 RNA polymerase (Promega); 
and 0.1 µCi [35S] methionine. Reactions were mixed either by pipeting up and down and 
stirring with the pipet tip or by gently vortexing with a variable speed vortex so as not to 
introduce bubbles. After reactions were assembled on ice they were transferred to either 
30 or 37 °C water baths (as indicated) for the indicated times. For reactions where re-
initiation of protein synthesis was stopped, 60 µM aurintricarboxylic acid (ATA) was 
added and mixed by pipeting up and down and stirring with the pipet tip. Geldanamycin 
treatment was performed, when possible, concurrently with coupled 
transcription/translation reactions since treatment does not affect protein synthesis in this 
system. However, when clofibric acid, pep<j>, BSA, RCM-BSA, or heat shock (HS) was 
used, treatments were restricted to after re-initiation was inhibited and polyribosomes 
were allowed to run off, since most of these inhibit protein synthesis if initiated before 
synthesis was completed. Drugs, peptides, or proteins were added directly to protein 
synthesis reactions; however, heat shock treatment was conducted by transferring the 
tube to a water bath at 42 °C for the indicated time. 
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Immunoadsorptions 
Antibodies against p561ct, penta-His epitope tags, FKBP52 (ECl), or p23 (JJ3 and 
JJ5) were prebound to 15 µl (packed volume) of agarose resin conjugated with goat anti-
mouse IgG antibodies, and washed once with 10 mM PIPES (pH 7.0), 50 mM NaCl, once 
with 10 mM PIPES (pH7.0), 500 mM NaCl, and twice with 10 mM PIPES (pH 7.0), 50 
mM NaCl. Washed immunoresins were mixed on ice for 1-2 hours with 30-50 µl protein 
synthesis reactions (as indicated) which had been chilled and clarified by a 5 minute spin 
at 10000-14000 x g at 4 °C. After mixing, immunoresins were washed 5 times with 10 
mM PIPES (pH 7.0), 0.05-0.5% Tween-20, and the indicated concentrations of NaCl and/ 
or sodium molybdate. Absorbed materials were eluted by boiling for 5 minutes in SOS-
PAGE sample buffer and separated by SOS-PAGE. Protein bands were transferred from 
the gel to PVDF membranes and analyzed by autoradiography or immunoblotting as 
indicated. 
p561ck kinase assays 
Mature or nascent [35S] labeled p561ck was immunoprecipitated as stated above and 
washed 3-4 times with IP wash buffer [50 mM HEPES pH 7.4, 2% (v/v) Triton X-100, 
120 mM NaCl, 1 mM sodium vanadate] and 2 times with kinase wash buffer (100 mM 
PIPES pH 7 .0, 10 mM MnC12). Washed immunoresins were then mixed with kinase 
assay mix (100 mM PIPES pH 7.0, 10 mM MnC12, 100 µg denatured enolase (2 µg/µl) 
10-50 µM nonradioactive ATP, and 10-15 µCi [y-32P]ATP) in a room temperature H20 
bath for 6 minutes. Kinase reactions were stopped by addition of boiling SOS-PAGE 
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sample buffer. Samples were separated by SDS-PAGE, transferred to PVDF membranes, 
and analyzed by autoradiography. 
Results 
Chaperone interactions with immature p561ck kinase client. 
Previous work done with the progesterone receptor (PR) ([31, 45, 192] and 
reviewed in chapter 1) found PR to initially form a complex with Hsp70 and Hsp40, and 
proceed through a dynamic cycle of chaperone interactions necessary to keep the receptor 
in a state competent to bind hormone. In similar fashion, many of the same components 
were found complexed with the estrogen receptor, the aryl hydrocarbon receptor, and the 
Fes tyrosine kinase [45]. In order to compare p561ck interactions with those reported for 
the steroid hormone receptors and the Fes kinase as well as extend those 
characterizations, we modeled p561ck folding in nuclease treated RRL. 
Rabbit reticulocyte lysate is a cell free system of mammalian origin in which 
controlled protein synthesis can be conducted. Rabbit reticulocyte lysate is also rich in 
chaperones and can generate active folded proteins of many types. The previous chapter 
reported the different co-translational interactions of three different protein substrates 
with chaperones. Here we further characterized post-translational interactions between 
the kinase p561ck and molecular chaperones. In order to determine whether p561ck 
interacted with chaperones after translation, protein synthesis in RRL was performed in 
the absence of puromycin. Protein synthesis generally shuts off in RRL after 15-20 
minutes at 37 °C as shown in Figure 14. Incorporation of [35S] methionine plateaued after 
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Figure 14. Protein Synthesis in RRL at 37 °C. 
Nuclease treated RRL was programmed with ( •) or without ( o) p561ck cDNA and 
incubated in a 37 °C water bath for 30 minutes in the presence of [35S] methionine 
to radiolabel newly synthesized p561ck. 1 µl of RRL was spotted on to filter paper 
at the indicated times and precipitated in 10% TCA. Filter papers were washed, 
bleached with 15% hydrogen peroxide, and submerged in liquid scintillation 
cocktail for counting 
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20 minutes of synthesis at 37 °C. To detect very early post-translational interactions with 
p561c\ nuclease treated RRL was programmed with plasmid DNA containing cDNA 
encoding full-length p561ck. Synthesis was conducted for 20 minutes at 37 °C and an 
aliquot of the synthesis reaction was immediately immunoprecipitated with anti-p561ck 
antibodies (Figure 15, lanes 1 and 2). The remainder of the protein synthesis reaction was 
incubated for 1 hour at 37 °C and then immunoprecipitated (Figure 15, lanes 3 and 4). As 
can be seen in the autoradiogram (bottom panel labeled [35S] p561ck) only full-length p561ck 
was captured. Chaperones that co-absorbed with p561ck were eluted and separated by 
SOS-PAGE. Hsp90, Hsp70, and p50cdc37 all co-immunoprecipitate with p561ck after 20 
minutes of synthesis, and after an hour incubation at 37 °C the quantity of these 
chaperones dramatically dropped (Figure 15, lane 2 versus lane 4 and Figure 16, lanes 3 
and 4 versus lanes7 and 8). The temporal chase of Hsp90 has been reported for p561ck 
[174]; however, the interactions of Src family kinases with Hsp70 have not been well 
characterized. The importance of Hsp90 function for temporally immature p561ck during 
biogenesis is also shown by GA inhibition of p561ck kinase activity ([27]; and Figures 19 
and 20, lane 5 in both). Hsp90 chaperone complexes with substrates and co-chaperones 
are often stabilized by addition of molybdate during immunoprecipitation. Molybdate 
stabilizes the Hsp90 complexes to high ionic strength [24, 25]; however, the kinase 
complex shown in Figure 15 is stable to washes in high ionic strength (0.5 M NaCl) 
buffers even in the absence of stabilizing agents (Figure 16, lane 4). These results 
indicate that Hsp90 and p50cdc37 form a complex with newly synthesized p561ck that is 
stable in 0.5 M salt, but not with mature p561ck (Figure 16, lanes 7 and 8). This complex 
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Figure 15. Time Course of Chaperone Interactions with Wild Type p561ck Kinase. 
Nuclease treated RRL was programmed with (+, lanes 2 and 4) or without (-, 
lanes 1 and 3) p561ck cDNA and allowed to synthesize protein for 15 minutes at 37 
QC in the presence of [35S] methionine to radiolabel newly synthesized p561ck. 
Aliquots of the protein synthesis reactions were immediately clarified and mixed 
with goat anti-mouse IgG coupled agarose, which was prebound with mouse anti-
p561ck (lanes 1 and 2). The remainder of the protein synthesis reactions was 
incubated for 1 hour at 37 QC and then immunoprecipitated as described above 
(lanes 3 and 4). Proteins bound to the immunopellets were eluted with sample 
buffer and separated by SOS-PAGE. Gels were electro-transferred to PVDF 
membranes and immunoblotted with the indicated antibodies [anti-Hsp90 (OSU 
mouse ascites fluid), anti-Hsp70 (N27), or anti-p50cdc37 (OSU mouse ascites fluid) 
as indicated on the right side of the panel]. [35S]p561ck was detected by 
autoradiography (see bottom panel labeled [35S]p561ck on the right side of the 
panel). The location of the molecular weight standards is marked on the left side 
of the panel. 
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Figure 16. Salt-stable Association of Hsp90 and p50Cdc37 with p561ck Maturation 
Intermediates. 
Nuclease treated RRL translation reactions were (lanes 3, 4, 7, and 8), or were not 
(lanes 1, 2, 5, and 6) programmed with p561ck cDNA. After 25 minutes of 
synthesis in the presence of [35S] methionine, reinitiation was inhibited with ATA 
(60 µM) and reactions were either immediately immunoabsorbed with anti-p561ck 
antibodies (lanes 1-4) or incubated further (chase) for 60 minutes (lanes 5-8) prior 
to immunoabsorption. Immunopellets were washed with buffers containing 0.5 M 
NaCl (labeled H even-numbered lanes) or without (labeled L, odd-numbered 
lanes). [35S]p561ck was detected by autoradiography (see middle panel, labeled 
[ 35S]p561ck on the left side of the panel). Hsp90 and p50cdc37 were detected by 
immunoblotting with anti-Hsp90 or anti-p50cdc37 antibodies (see left side of the 
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with p561ck kinase is differ~nt than the salt labile complex Hsp90 and p50cdc37 form in the 
absence of substrate kinases [ 46]. 
We were interested in determining the effects of chaperone binding drugs on 
substrate kinase chaperone complexes. As stated in Chapter 1, GA binds to Hsp90 in the 
ADP bound conformation and as shown in Chapter 2, GA treatment depletes cellular 
levels of p561ck from T cells and disrupts the salt stable interaction of Hsp90 with newly 
synthesized p561ck synthesized in RRL [26]. To extend the characterization of the effects 
of GA treatment to the Hsp90 co-chaperone p50cdc37 and the fellow chaperone Hsp 70, we 
treated RRL's translating p561ck with GA. The salt stable chaperone complex formed 
with p561ck was destabilized in the presence of high salt (Figure 17, lane 6 versus lane 8). 
Interestingly, even when the complex was washed with low salt buffer (0 M) the p50cdc37 
component was lost and the amount of Hsp90 captured was reduced (Figure 17, lane 4). 
However, when p50cdc37 was captured out of GA treated RRL in the absence of kinase the 
complex with Hsp90 was not affected; although, it is important to emphasize that this 
complex is much more salt labile in the absence of kinase [46]. 
Hsp70 has a functional interaction with newly synthesized p561ck. 
The Hsp70 component of the kinase complex was examined similarly with the 
treatment of chaperone binding drugs. Geldanamycin was used again and the Hsp70 
binding drug clofibric acid (CIA) was included in the study. Clofibric acid has been 
reported to disrupt Hsp70 interactions with HRI affecting its regulation of HRI kinase 
activity [179]. A loss of p50Cdc37 can be seen with GA treatment (Figure 18, lane 4-control 
versus lane 8) and a little loss of Hsp90, since this was done at 150 mM salt. In contrast 
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Figure 17. Kinase-Chaperone Heterocomplexes Formed in the Presence of 
Geldanamycin. 
Nuclease treated RRL was programmed with(+, even-numbered lanes) or without 
(- odd-numbered lanes) ~-p561ck cDNA and allowed to synthesize protein with 
[ 35S] methionine briefly in the presence (+, lanes 3, 4, 7, and 8) or absence (-, 
lanes 1, 2, 5, and 6) of geldanamycin. After synthesis RRLs were 
immunoadsorbed with antibodies against the penta-His peptide and washed with 
(lanes 5-8) or without (lanes 1-4) 0.5 M NaCL Immunocomplexes were analyzed 
by western blotting to detect Hsp90, p50Cdc37 (marked on the left side of the panel), 
or autoradiography to detect [ 35S] labeled H6-p561ck (bottom panel marked [35S]H6-
p561ck on the left side of the panel). The location of the molecular weight standards 
(kDa) is marked on the right side of the panels. Antibody heavy chains were 
eluted from the immunoresins as well and are also marked on the left side of the 
panels (ab he). 
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Figure 18. Drug Effects On Chaperone Interactions with p561ck Kinase. 
Nuclease treated RRL was programmed with ( +, lanes 2, 4, 6, 8, and 10) or 
without(-, lanes 1, 3, 5, 7, and 9) p561ck cDNA and allowed to synthesize protein 
for 8 minutes at 37 °C in the presence of [35S] methionine to radiolabel newly 
synthesized p561ck. Initiation of protein synthesis was inhibited with ATA ( 60 µM) 
and synthesis of initiated messages was completed by a 5 minute incubation at 37 
°C. RRLs were separated into equal aliquots and treated without (lanes 1 and 2) or 
with DMSO (control lanes 3 and 4), H20 (control, lanes 5 and 6), geldanamycin 
(GA lanes 7 and 8), or clofibric acid (CIA, lanes 9 and 10). Immunoprecipitations 
were washed, eluted with sample buffer, and separated by SOS-PAGE. Proteins 
were electroblotted on PVDF and immunoblotted with the indicated antibodies 
[marked on the right side of the panel: anti-Hsp90 (OSU mouse ascites fluid), anti 
Hsp70 (N27), or anti-p50cdc37 (OSU mouse ascites fluid)]. [35S] labeled p561ck was 
detected by autoradiography (marked on the right side of the panel). The location 
of the molecular weight standards is marked on the left side of the panel. 
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the amount of Hsp70 increased by 3 fold (Figure 18, lane 4-control versus lane 8). The 
levels of chaperones binding p561ck upon CIA treatment were not affected (Figure 18, lane 
6-control versus lane 10). It is thought that blocking the function of Hsp90, as done with 
GA treatment, causes an accumulation of Hsp70 on substrate due to an inability to pass 
from Hsp70 to Hsp90 during its normal chaperone mediated folding pathway. This is 
supported by our observation that more Hsp70 co-adsorbs with p561ck in GA treated 
lysate. Our inability to inhibit Hsp70 binding to p561ck could be due a difference in our 
observed interaction and that reported for HRI. It could also indicate that Hsp70 interacts 
with newly synthesized p561ck in a nonspecific manner and does not represent an 
important functional component of the complex. 
In order to test whether Hsp70 was a functional chaperone component of p561ck 
biogenesis, the kinase was synthesized in RRL and treated with CIA. As shown for the 
interaction of p561ck and Hsp70, the mature kinase does not interact with Hsp70 (Figure 
15, lane 4) suggesting that the mature kinase does not need Hsp70. Treatment of p561ck 
with either CIA or GA (a positive control) resulted in a 78% or 54% decrease in kinase 
activity (Figure 19, lanes 4 and 5 respectively), as measured by phosphorylation of the 
exogenous substrate denatured enolase. Autokinase activity measured by phosphorylation 
of p561ck itself resulted in similar inhibition (Figure 20). A comparison of inhibition of 
nascent versus mature p561ck kinase activity showed the mature kinase only lost 16% of 
its activity when treated with CIA (Figure 19, lane 2 versus 6) and 6% of its activity when 
treated with GA (Figure 19, lane 3 versus 7). This correlates with the interaction data and 
suggests that the mature p561ck kinase is much less dependent on Hsp70 and Hsp90 for 
function. Clofibric acid has other actions in addition to binding Hsp70, such as binding to 
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Figure 19. Drug Effects on p561ck Kinase Activity. 
Nuclease treated RRL was programmed with(+ lanes 2-7) or without (- lane 1) 
p561ck cDNA and allowed to synthesize protein for 12 minutes in the presence of 
[ 35S] methionine to radiolabel newly synthesized p561ck. Initiation of protein 
synthesis was inhibited with ATA (60 µM) and ribosomes were allowed to run off 
for 5 minutes at 37 CC. Protein synthesis reactions were separated into "nascent" 
and "mature" fractions. Nascent fractions were treated without (lanes 1 and 2) or 
with 1 % DMSO (lane 3), 15 mM clofibric acid (CIA, lane 4), or 89 µM 
geldanamycin (GA, lane 5) for 30 minutes at 37 CC. Mature fractions were 
incubated for 30 minutes followed by a 10 minute treatment with either 15 mM 
CIA (lane 6) or 89 µM GA (lane 7). Fractions were then clarified and mixed with 
anti-IgG coupled agarose prebound with anti-p561ck antibodies for 1 hour on ice. 
Immunoprecipitations were washed and kinase activity assayed with [y-32P]ATP 
and enolase as described in material and methods. Phosphorylated proteins were 
eluted and separated by SDS-PAGE and transferred to PVDF. Membranes were 
dried and exposed to autoradiography film. The location of the [35S]p561ck band is 
marked on the right side of the upper panel and the location of the [32P]enolase 
band is marked on the right side of the upper panel. 
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the Peroxisome Proliferator-Activator Receptor a (PPAR-a) [193-199], therefore other 
Hsp70 modulating agents and conditions were tested for effects on p561ck kinase activity. 
First, the specific Hsp70 binding peptide termed peptide <I> (pep<j> ), based on high affinity 
binding peptides identified by phage display libraries [200] and closely resembling the 
motif Hsp70 recognizes in substrates [201]. Second, reduced carboxy-methylated bovine 
serum albumin (RCM-BSA) imitates the structure and chemistry of denatured proteins 
recognized by Hsp70 during stress condition such as heat shock. Lastly, heat shock itself 
was also induced in the RRL system by incubating the lysate at 42 QC for 10 minutes. 
Pep<j> provided the most inhibition of all the conditions that modulate Hsp70 function, 
inhibiting 75% of the autokinase activity and 59% of the enolase phosphorylating activity 
(Figure 20, lane 2 versus 6). Only GA treatment provided more inhibition, 77% and 65% 
inhibition of the autokinase and enolase phosphorylating activitiy (Figure 20, lane 4 
versus 5). Both RCM-BSA and heat shock (HS) inhibited p561ck auto-kinase activity by 
37% and 72% respectively (Figure 20, lanes 8 and 9). These results further support the 
importance of Hsp70 in folding and biogenesis of an active p561ck kinase. 
Previous work presented by our laboratory has shown that the constitutively 
active transforming mutant kinase p561ckp505, in which the regulatory tyrosine at position 
505 is mutated to a phenylalanine, has a prolonged and greater dependence on Hsp90 
function at 37 QC than does the wild type p561ck kinase. In order to test whether this 
dependence of the mutant p561ckp505 kinase on Hsp90 for maintenance of kinase activity 
at physiological temperatures corresponded with a greater dependence on Hsp70 we 
assayed kinase activity in the presence and absence of drugs. The mature wild type p561ck 
kinase showed no disactivation of its enolase phosphorylating activity in the presence of 
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Figure 20. Effects of Hsp70 Modulators on p561ck Kinase Activity. 
Nuclease treated RRL was programmed with(+ lanes 2-10) or without (- lane 1) 
p561ck cDNA and allowed to synthesize protein for 10 minutes at 37 °C in the 
presence of [35S] methionine to radiolabel newly synthesized p561ck. Initiation of 
protein synthesis was inhibited with ATA and ribosomes were allowed to run off 
for 4 minutes at 37 °C. Protein synthesis reactions were separated into equal 
aliquots and matured in the presence of H20 (Con, lane 2), 15 mM clofibric acid 
(CIA, lane3), 1 % DMSO (lane 4), 89 µM geldanamycin (GA, lane 5), 0.5 mM 
peptide <I> (pep<j> lane 6), 1.5 mg/ml bovine serum albumin (BSA, lane 7), 1.5 
mg/ml reduced carboxy methylated-BSA (RCM-BSA, lane 8), or in RRL at the 
heat shock temperature of 42 °C (HS, lane 9). Fractions were then clarified and 
mixed with anti-IgG coupled agarose prebound with anti-p561ck antibodies and 
assayed for kinase activity as described above. A fraction of the untreated p561ck 
was treated with 15 mM CIA during the kinase assay as a control (lane 10). The 
location of [35S]p561ck is labeled on the right side of the top panel. The location of 
[ 32P]p561ck is marked on the right side of the middle panel. The location of 
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CIA or GA (Figure 21A, bottom band lanes 2-5). A little (21 % ) of the wild type p561ck 
autokinase activity was inhibited by CIA but not by GA treatment (Figure 21A, top band 
lane 3 versus 4 and lane 2 versus 5). In contrast to their effects on wild type p561c\ both 
CIA and GA treatment decreased the ability of the p561ckp505 mutant to phosphorylate 
enolase by 97% and 56% respectively (Figure 21A, lane 7 versus 8 and lane 6 versus 9). 
This result indicates that the p561ckp505 mutant kinase depends on both Hsp70 and Hsp90 
to maintain kinase activity at physiological temperatures. 
Kinase activity is not essential for chaperone interactions. 
Figure 21 showed that the chaperone dependence of a constitutively active kinase 
mutant was greater than that of the regulated wild type kinase. Two possible reasons for 
this greater dependence on chaperones Hsp70 and Hsp90 are addressed here. One is that 
the active kinase may be the preferred conformation recognized by the chaperone 
machinery, probably due to instability in the structure. Alternatively, the regulatory 
phosphorylation site in the C-terminal tail may inactivate the kinase and thereby add 
stability to the kinase allowing it to mature to an Hsp90 independent state. The first 
reason would predict that an inactive kinase should not interact with chaperones and the 
second reason would predict an inactive kinase should not mature to an Hsp90 
independent state. In order to test these predictions another p561ck kinase mutant was used 
in which the active site lysine (K) 273 was conservatively mutated to an arginine (R). 
This mutant is inactive as a tyrosine kinase (reviewed in [202]). A time course 
experiment as described for Figures 15 and 16 was conducted and the presence of Hsp90 
and p50cdc37 in immature and mature kinase complexes was examined by western blotting. 
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Figure 21. Disactivation of Wild Type and F505 p561ck Kinase by Clofibric Acid and GA. 
(A) Nuclease treated RRL was programmed without (- lane 1) or with wild type 
(wt lanes 2-5) or F505 (lanes 6-9) p561ck cDNA and allowed to synthesize protein 
for 20 minutes at 37 °C in the presence of [35S] methionine to radiolabel newly 
synthesized p561ck. Initiation of protein synthesis was inhibited with ATA, 
ribosomes were allowed to run off, and wild type or mutant kinase was matured 
for 1 hour at 37 °C. Protein synthesis reactions were separated into equal aliquots 
and treated with 1 % DMSO (lanes 2 and 6), H20 (lanes 3 and 7), 15 mM CIA 
(lanes 4 and 8), or 89 µ.M GA (lanes 5 and 9) for 1 hour at 37 °C. Aliquots were 
then mixed with anti-IgG coupled agarose prebound with anti-p561ck antibodies 
and assayed for kinase activity as described above. The location of the [32P]p561ck 
band and the [32P]enolase band are marked on the right side of the panel. (B) A 
fraction of the immunopellet that was used for each kinase assay was separated on 
another gel to show equal amounts of [35S] kinase were used in the kinase assay. 
Lanes 1, 3, 5, and 7 show [35S] wt p561ck and lanes 2, 4, 6, and 8 show [35S] F505 
mutant kinase input into the different kinase assays. {The [35S]p561ck band or bands 
are marked on the right side of the panel.) The different drug treatments for each 
immunopellet are labeled above the lanes: DMSO (lanes 1 and 2), H20 (lanes 3 
and 4), CIA (lanes 5 and 6), and GA (lanes 7 and 8). 
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Both Hsp90 and p50cdc37 formed a complex with the immature kinase (Figure 22 lane 2) 
and chased off the mature kinase within 60 minutes, as shown for wild type p561ck (Figure 
22 lane 4). This indicates that kinase activity is not the sole requirement for chaperone 
interactions. 
Other componenets of the immature p561ck kinase chaperone complex. 
We have identified Hsp70, Hsp90, and p50cdc37 as dynamic functional components 
necessary for the biogenesis of an active p561ck kinase. Other components of the Hsp90 
chaperone machinery reported to interact with steroid receptors and some protein kinases 
(p6ov-src, Raf, and Fes) include FKBP52, Cyp40, and p23 [45, 95, 203]. However, there is 
some disagreement as to whether the TPR containing immunophilins are part of the 
kinase chaperone complex [43, 44]. To determine whether the p561ck chaperone 
complexes contain these components histidine tagged p561ck was synthesized in RRL and 
immunoadsorbed using an anti-pentaHis antibody. It was found that adding the sequence 
for a six residue histidine tag to the 5'-end of the p561ck cDNA increased the translation 
efficiency and allowed for the generation of more kinase, and therefore better detection of 
co-adsorbing proteins. The mechanism of the increase in translation efficiency is 
unknown. Figure 23 shows the autoradiogram and the immunostained membrane of the 
samples eluted from the immunoprecipitation of H6- p561ck. Both low salt (no salt: Figure 
23, lanes 7-12) and high salt (0.5 M: Figure 23, lanes 1-6) washes were done and both 
GA (Figure 23: lanes 3, 4, 9, and 10) and Mo04 (Figure 23, lanes 5, 6, 11, and 12) were 
included in the characterization. As shown in the low salt samples, the immunophilins 
Cyp 40 and FKBP52 were brought down in the complex (Figure 23, lane 8); however, 
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Figure 22. Time Course of Chaperone Interactions with Kinase Inactive R273 p561ck 
Mutant. 
Nuclease treated RRLs were programmed with ( +, lanes 2 and 4) or without (-, 
lanes 1 and 3) p561ck_R273 cDNA and allowed to synthesize protein for 20 
minutes at 37 QC in the presence of [35S] methionine to radiolabel newly 
synthesized mutant p561ck. Aliquots of protein synthesis reactions were 
immediately clarified and mixed with immunoresins (0 min, lanes 1 and 2). In the 
remainder of the protein synthesis reactions initiation of protein synthesis was 
inhibited with ATA and mutant p561ck was matured for 60 minutes at 37 QC before 
immunoprecipitation as described above and in materials and methods (60 min, 
lanes 3 and 4). R273[35S]p561ck was detected by autoradiography (labeled 
[35S]p561ck_R273 on the right-hand side of the bottom panel). Hsp90 and p50cdc37 
were detected by immunoblotting with the appropriate antibodies and are labeled 
on the right-hand side of the top panel. The antibody heavy chain (HC, location 
marked on the right side of the top panel) also eluted from the immunoresin, and 
was detected by the secondary antibody. The location of molecular weight 
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Figure 23. Effects 'of Drugs on p561ck Interactions with Chaperones and Co-chaperones. 
Nuclease treated RRLs were programmed with ( +, lanes 2, 4, 6, 8, 10, and 12) or 
without (-, lanes 1, 3, 5, 7, 9, and 11) p561ck cDNA and allowed to synthesize 
protein for 20 minutes at 37 °C in the presence of [35S] methionine. Protein 
synthesis reactions were treated with indicated drugs [l % DMSO (lanes 1, 2, 7, 
and 8), 89 µM GA (lanes 3, 4, 9, and 10), and 20 mM N8i(Mo04) (lanes 5, 6, 11, 
and 12)] and mixed with immunoresins prebound with anti-His antibodies. Two 
sets of immunoprecipitations were prepared and subjected to different wash 
conditions. Lanes 1-6 were washed with a "High Salt" wash buffer (0.5 M NaCl). 
Lanes 7-12 were washed with a "Low Salt" wash buffer (0 mM NaCl). For both 
sets 20 mM N8i(Mo04) was included in the wash buffers for samples treated with 
molybdate (lanes 5, 6, 11, and 12). Immunoabsorbed proteins were eluted with 
SDS-PAGE sample buffer and separated by SDS-PAGE. Protein bands were 
electroblotted to PVDF membrane and subjected to autoradiography (bottom 
panel, labeled [35S]H6p561ck on the right side of the panel) and immunostaining 
with indicated antibodies (top panel, labeled on the right side of the panel: Hsp90 
OSU mouse ascites fluid, Hsp70 N27, FKBP52 ECl, p50cdc37 OSU mouse ascites 
fluid, polyclonal Cyp40 from Affinity BioReagents). The location of the 
molecular weight standards is marked on the right side of the top panel. 
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GA treatment disrupted this interaction much like the disruption seen for p50cdc37 (Figure 
23, lane 10). Molybdate did not stabilize this complex and in fact less Cyp 40 and 
FKBP52 were recovered, although, it did enhance the interaction of both Hsp90 and 
p50cdc37 with the kinase (Figure 23, lane 12). Interestingly the immunophilin interactions, 
unlike p50cdc37, were not stabile in high salt (Figure 23, lanes 1-6). Unsuccessful attempts 
were made to detect p23 by immuno-staining. 
The poor detection of FKBP52 by the ECl antibody and the lack of detection of 
p23 in Figure 23 made identification of these interacting partners uncertain. Most 
experiments done by immunoprecipitating p561ck failed to detect FKBP52 and all failed to 
detect p23. Detection of FKBP52 was only possible when high quantities of p561ck kinase 
were synthesized. The FKBP52 and p23 antibodies are reported to be much better at 
immunoprecipitating than immuno-blotting. For this reason immunoprecipitations of 
FKBP52 and p23 were conducted and the [35S]p56lck kinase was detected by 
autoradiography. 
Immunoprecipitation of FKBP52 also enabled us to determine whether both 
FKBP52 and p5occtc37 were components of the same complex on the kinase or if they 
interacted with the kinase in independent complexes. This is an important issue since 
previous reports have suggested that p50cdc3l and TPR containing proteins, such as 
FKBP52 and Cyp40 compete for the same or topologically adjacent sites on Hsp90. 
Silverstein et al. [44] concluded that p50cdc37 and TPR containing proteins are mutually 
exclusive components of the Hsp90 machinery that sterically hindered the binding of the 
other due to the close proximity of their binding sites on Hsp90. Figure 24 shows the 
immunoprecipitation of FKBP52 with the monoclonal ECl antibody. In contrast to the 
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results of Silverstein and co-workers, our lab has shown that p50cdc37 forms a significant, 
but salt labile component, of the native (substrate-free) FKBP52 complex [46]. To further 
l. 
our characterization, we show that anti-FKBP52 antibodies co-adsorbed p561ck in an 
immune specific fashion (Figure 24: lane 4 versus 5, and lane 8 versus 9), and the 
complex was stable to washes at 150 mM NaCL A comparison of the amount of Hsp90 
co-absorbed with FKBP52 in the presence and absence of kinase (Figure 24: lane 2 
versus 4, and lane 6 versus 8) show more Hsp90 complexed with FKBP52 in the presence 
of p561ck. The same analysis was done for p50Cdc37• Some p50cdc37 associated with FKBP52 
without kinase (Figure 24, lanes 2 and 6), but when p561ck was included (Figure 24, lanes 
4 and 8) there was a significant increase in the amount of p50cdc37 associated with 
FKBP52. In addition, the Hsp90 complex stabilizing agent molybdate failed to stabilize 
this complex as indicated by the loss of some p561ck and p50cdc37 upon addition of 20 mM 
Nai(Mo04) (Figure 24, lanes 6-9). To further this characterization a time course, as 
described for Figures 15, 16, and 22, was conducted to determine whether p561ck chased 
off of the FKBP52 complex. Immediately after synthesis p56Ick interacted with FKBP52 
along with Hsp90 and p50cdc37 (Figure 25, lane 4). After 60 minutes neither p561ck kinase 
nor p50cdc37 associated with FKBP52, although Hsp90 and Hsp70 were still associated 
(Figure 25, lane 8). These results suggest that p561ck dramatically increases the association 
of p50cdc37 with the FKBP52 complex. 
Figure 26 shows the co-immunoprecipitation of p561ck with p23 (lane 1). Hsp90 
and p50cdc37 also interacted with p23. Treatment with molybdate did not stabilize the 
interaction of p23 with p561ck or p50cdc37, but did slightly increase the amount of Hsp90 
associated with p23 (Figure 26, lane 3). Treatment with GA disrupted the association of 
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Figure 24. Molybdate Destabilization of Chaperone and p561ck Complexes. 
Nuclease treated RRL was programmed with ( +: lanes 4, 5, 8, and 9) or without (-
: lanes 2, 3, 6, and 7) p561ck cDNAs, and allowed to synthesize protein for 25 
minutes at 30 °C in the presence of [35S] methionine. Protein synthesis reactions 
were aliquoted and either treated with [20 mM N3z(Mo04) (lanes 6-9)] or without 
[(O mM N3z(Mo04) lanes 2-5)] molybdate. RRL was separated into equal aliquots 
and were then immunoprecipitated with the immune monoclonal antibody ECl (I: 
lanes 2, 4, 6, and 8) or with the non-immune antibody (NI: lanes 3, 5, 7, and 9) 
and analyzed as described above. [35S]H6p561ck was detected by autoradiography 
(bottom panel) and is labeled on the right-hand side of the panel. Hsp90, p50cdc37, 
and Cyp40 were detected by immunostaining and are labeled on the right-hand 
side of the top panel. The location of the molecular weight standards is marked on 
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Figure 25. Time Course of FKBP52 Interaction with p561ck Kinase. 
Nuclease treated RRL was programmed with(+: lanes 3, 4, 7, and 8) or without (-
: lanes 1, 2, 5, and 6) p561ck cDNAs and allowed to synthesize protein for 20 
minutes at 37 °C in the presence of [35S] methionine. Aliquots of protein synthesis 
reactions were immediately mixed with immunoresins prebound with the immune 
monoclonal antibody ECl (I: lanes 2 and 4) or with the non-immune antibody 
(NI: lanes 1 and 3) for 1 hour on ice, washed, and eluted with SDS-PAGE sample 
buffer. The remainder of the protein synthesis reactions was treated with ATA to 
inhibit initiation, and p561ck was matured for 60 minutes at 37 °C. Matured p561ck 
was immunoprecipitated and eluted as decribed above. Eluant was separated by 
SDS-PAGE, electroblotted and analyzed by autoradiography and immunostaining 
as described above. [35S]H6p561ck was detected by autoradiography (bottom panel) 
and is labeled on the side. Hsp90, Hsp70, FKBP52, p50cdc3l were detected by 
immunostaining and are marked on the right side of the top panel. The location of 
the molecular weight standards is marked on the left side of the top panel. 
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Figure 26. Interaction of p23 with p561ck Kinase and Disruption by GA. 
Nuclease treated RRL was programmed with p561ck cDNAs and allowed to 
synthesize protein for 20 minutes at 37 °C in the presence of [35S] methionine. 
After synthesis reactions were treated with 20 mM Na2Mo04 (lanes 3 and 4), 89 
µ,M GA (lanes 5 and 6), or nothing (lanes 1 and 2). Samples were immediately 
clarified and mixed with immunoresins prebound with the immune antibody JJ3 
(monoclonal p23 antibody labeled "I" odd-numbered lanes) or the non-immune 
antibody ("NI " even-numbered lanes) for 1 hour on ice. Non-treated and GA 
treated immunopellets (lanes 1, 2, 5, and 6) were washed with 150 mM NaCl and 
Mo04 treated immunopellets (lanes 3 and 4) were washed with 100 mM NaCl and 
20 mM Na2Mo04 • [ 35S]p561ck was detected by autoradiography (bottom panel, 
labeled on the right side). Hsp90, p50cdc37 , and p23 were detected by 
immunoblotting and are labeled on the right side of the upper panels. The location 
of the molecular weight standards is marked on the left side of the upper panels. 
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Hsp90, p50Cdc37, and p561ck with p23 (Figure 26, lane 5), suggesting Hsp90 mediates the 
interaction of p561ck and p50cdc37 with p23. 
p561ck kinase domain interactions with chaperone components. 
Early work characterizing the interactions between the viral p6ov-src kinase and 
Hsp90 and p50cdc37 localized the interactions to the kinase domain (reviewed in [94]). 
Hsp90 and p50cdc37 interact with the kinase domains of other protein kinases as well [ 44, 
45, 95]. Figures 12 and 13 in the chapter 3 also localize the interactions of Hsp90 and 
p50cdc37 with the kinase domains of p561ck and HRI. Here we try to further define the part 
or parts of the kinase domain that are necessary for chaperone interactions. The structure 
of the kinase domains of most eukaryotic protein kinases are very similar and can be 
separated into two subdomains, or lobes: the N-terminal lobe (N-lobe) and the C-terminal 
lobe (C-lobe). Clones of each lobe were made with a His-tag and translated in RRL as 
described before. Figure 27 shows the immunoprecipitation of each of the lobes in 
comparison with both full-length p561ck and the kinase catalytic domain (Figure 27: lanes 
2 and 3, respectively). Hsp90 and p50cdc37 both co-immunoprecipitated with the full-
length kinase, the catalytic domain, and the N-terminal lobe of the catalytic domain, but 
not with the C-terminal lobe of the catalytic domain (Figure 27: lanes 2, 3, 4, and 5 
respectively). Interestingly, the Cyp40 interaction favored the catalytic domain as shown 
by the increase in the amount binding, and it was greater than the amount for either the 
full-length p561ck or the N-lobe, even when normalized for the amount of Hsp90 and 
p50cdc37• Immunoprecipitations with both FKBP52 and p23 antibodies (Figures 28 and 29 
respectively) indicate that these co-chaperones interact specifically with the N-terminal 
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Figure 27. p561ck Kinase Lobe Interactions with Hsp90 and p50cdc37• 
Nuclease treated RRL was programmed with full-length (FL, lane 2) Ri,-p561c\ 
His-tagged catalytic domain (Cat, lane 3), His-tagged N-terminal lobe (NL, lane 
4), or His-tagged C-terminal lobe (CL, lane 5) cONAs or without template (NT, 
lane 1). After protein synthesis at 37 °C for 20 minutes in the presence of [35S] 
methionine reactions were adjusted to 20 mM Na2Mo04 and immediately clarified 
and mixed with immunoresins preabsorbed with antibodies against the penta-His 
antigen for 1 hour on ice. Immunoresins were washed, eluted with SOS-PAGE 
sample buffer, and separated by SOS-PAGE. [35S] labeled p561ck constructs were 
detected by autoradiography (bottom panel, labeled on the right side). Hsp90, 
p50Cdc37, and Cyp40 were detected by immunostaining and are labeled on the 
right-hand side of the top panels. The location of the molecular weight standards 
is marked on the left side of the top panels. 
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Figure 28. Interaction of p561ck Fragments with FKBP52. 
Nuclease treated RRL was programmed with the ~-p561ck catalytic domain (Cat, 
lanes 3 and 4), ~-N-terminal lobe (N-lobe, lanes 5 and 6), H6-C-terminal lobe (C-
lobe, lanes 7 and 8) cDNAs or without (No Temp, lanes 1 and 2) template. After 
protein synthesis in the presence of [35S] methionine for 20 minutes at 37 °C, 
reactions were adjusted to 20 mM Na2Mo04 and immediately clarified and mixed 
with immunoresins preabsorbed with the immune monoclonal antibody ECl ("I" 
even-numbered lanes), or the nonimmune antibody ("NI" odd-numbered lanes). 
Immunoresins were washed, eluted, and separated by SOS-PAGE. [35S] labeled 
p561ck constructs were detected by autoradiography (top panel) and labeled on the 
right-hand side. Hsp90 and p50cdc37 were detected by immunostaining and are 
labeled on the right-hand side (bottom panels). The location of the molecular 
weight standards is marked on the left side of the top panel. 
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Figure 29. Interaction of p561ck Fragments with p23. 
Nuclease treated RRL was programmed with the H6-p561ck full-length (FL, lanes 3 
and 4), H6-p561ck catalytic domain (Cat, lanes 5 and 6), H6-N-terminal lobe (N-
lobe, lanes 7 and 8), H6-C-terminal lobe (C-lobe, lanes 9 and 10) cDNAs or 
without (No Temp, lanes 1 and 2) template. After protein synthesis in the 
presence of [35S] methionine for 20 minutes at 37 °C reactions were adjusted to 20 
mM Na2Mo04 and immediately clarified and mixed with immunoresins 
preabsorbed with the immune monoclonal antibody JJ3 ("I" even-numbered 
lanes), or the nonimmune antibody ("NI" odd-numbered lanes). Immunoresins 
were washed, eluted, and separated by SDS-PAGE. [35S] labeled p561ck constructs 
were detected by autoradiography (top panel) and labeled on the right-hand side. 
Hsp90 and p50cdc37 were detected by immunostaining and are labeled on the right-
hand side (bottom panel). The location of the molecular weight standards is 
marked on the left-hand side of the both panels. 
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lobe of the catalytic domain (Figure 28, lanes 5 and 6; Figure 29, lanes 7 and 8). The 
nonspecific binding of the C-terminal lobe in these experiments was so high that it was 
not possible to determine specificity of binding (Figure 28, lanes 7 and 8; Figure 29 lanes 
9 and 10); however, since Hsp90 and p50cdc37 did not interact with the C-terminal lobe 
FKBP52 and p23 probably do not either. 
Discussion 
Several subtle and more obvious conclusions can be drawn from the results 
presented here. Figures 15-18 and 23-26 document the chaperone and co-chaperone 
interactions with immature p561ck. Immature p561ck interacts with Hsp70, Hsp90, and p23, 
many of the same components reported to interact with many of the steroid hormone 
receptors (ER-[45], GR-[32], PR-[31], and AR-[47, 204]) and other protein kinases (Raf-
[95], HRI-[205], Fes-[45]). We also characterized the interaction of p50cdc37, the "protein 
kinase-targeting subunit of Hsp90" which is thought to be specific to Hsp90/kinase 
substrate complexes [101]. The p50cdc37 interaction with p561c\ like the Hsp90 interaction, 
was stable to salt washes up to 0.5 M. We did not attempt higher salt concentrations. This 
argues against an electrostatic interaction between chaperones and client kinase and 
agrees with the idea that Hsp90 recognizes hydrophobic patches in its clientele. The fact 
that Hsp90 interaction with p5oct1c37 in the absence of substrate is more salt labile, a 30% 
loss at 150 mM NaCl [46], suggests this interaction may be more electrostatic in nature. 
These observations together indicate that p50cdc37 interacts with the p561ck bound Hsp90 
complex more than passively through Hsp90. The same cannot be said for the 
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immunophilin or p23 interactions since they do not show an increased stability to high 
salt in the presence of p561ck. p50cdc37 is an active member of the Hsp90 machinery as 
suggested by the functional dependence some kinases have for p50cdc37 [99-101]. 
Our study of the immunophilin components of the p561ck _chaperone complex goes 
against one of the current models of Hsp90 function. Owen-Grillo et. al. [ 43] proposed 
that steroid receptors associate with immunophilin containing Hsp90 complexes and 
kinases associate with p50cdc37 containing Hsp90 complexes [43, 95,206]. In 
contradiction to this model, we show FKBP52 and Cyp40 associated with p561c\ a 
finding consistent with other reports of immunophilin interactions with kinases [45, 205, 
207]. As an extension of this model Siverstein et al. [ 44] proposed that p50cdc37 and TPR 
containing cohorts, such as FKBP52 and Cyp40 compete for the same or topologically 
adjacent sites on Hsp90. Surprisingly, p50cdc37 associated with the FKBP52 complex and 
was significantly increased when p561ck was present. This finding suggests that the 
presence of p561ck enhanced this interaction, and that p5oct1c37 and FKBP52 are not 
mutually exclusive on Hsp90 complexes. 
Our observation that both FKBP52 and Cyp40 associate with p561ck raised the 
possibility that both were in the same Hsp90 complex. Both FKBP52 and Cyp40 
associated with p561ck when the immature kinase was immunoprecipitated; however, 
when FKBP52 immunoprecipitations were blotted for Cyp40, no Cyp40 was detected. 
This finding suggests that the proteins are in different Hsp90 complexes, a possibility 
supported by a report that the immunophilin components compete for binding to Hsp90 
[72]. However, identification of a 1:1 stoichiometry for TPR containing proteins and 
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Hsp90 monomers again raises the possibility of mixed hetero-immunophilin containing 
Hsp90 dimers. 
GA treatment of these complexes with immature p561ck rendered them much more 
salt labile. p50cdc37, FKBP52, Cyp 40, and p23 all washed off the p561ck complex at O M 
salt in the presence of GA, and Hsp90 washed off at 0.5 M in the presence of GA. These 
results suggest the co-chaperone interactions are mediated by Hsp90. p50cdc37 is the only 
Hsp90 cohort known to directly interact with kinase clients [101], but even this 
interaction was disrupted by GA. Only Hsp70 retained a salt stable interaction with p561ck 
in the presence of GA. Hsp70 interacted with p561ck independent of Hsp90 and in the 
absence of Hsp90 it appeared to increase its association. It has been proposed that GA 
treatment may cause Hsp90 substrates to accumulate in an Hsp70 bound reiterative cycle 
unable to pass to Hsp90 due to this inhibition. All of the chaperone components also 
chased off of the mature p561ck within an hour incubation at 37 °C. However, the 
p561c~505 mutant, which is reported to have a prolonged conditional dependence on 
Hsp90, showed a prolonged dependence on Hsp70 function for kinase activity at 37 °C 
[27]. 
Other Hsp90 substrates, such as the steroid receptors and the serine/threonine 
kinase HRI, however, are reported to have prolonged maintenance interactions with these 
chaperones until some maturational event occurs allowing them to become chaperone 
independent. These interactions are dynamic, however, and do not represent static 
holding complex awaiting a stabilizing event, rather the substrates in this model go 
through cycles of binding, folding, and release until they achieve a state stable and 
independent of the need for chaperone folding. For the steroid receptors this event is 
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ligand binding and for HR.I it is phosphorylations associated with heme-deficiency [33, 
172, 179]. It is assumed that p561ck also undergoes some maturational event or events, 
which allow it to gain chaperone independence, an event that occurs fairly rapidly in 
RRL. One possibility is phosphorylation of the regulatory 505 tyrosine. Hartson et. al. 
[27] proposed this due to the instability of mature p561ck kinase which had the 505 
tyrosine mutated to phenylalanine. Mature p561c"F505 lost activity upon treatment with 
GA, the Hsp90 inhibitory drug [27]. Here we show a similar loss of activity upon 
treatment with CIA, an Hsp70 inhibitory drug, indicating that both Hsp70 and Hsp90 are 
necessary for nascent folding of both kinases but, are required for the continued 
maintenance of only the mutant kinase. Other results from our laboratory demonstrate 
that a similar mutation in the Hck Src-family kinase, also has a requirment for continued 
maintenance by Hsp90 at 37 °C [143]. The F505 mutation or F527 mutation in p60S'c is 
the main alteration associated with converting p60src and p561ck into oncogenic kinases 
[208]. Oncogenic transformation by these kinases can be reverted by treatment with GA 
[26, 110]. Phosphorylation of the 505 tyrosine represses the kinase activity by inducing 
the binding of the SH2 domain, the phosphotyrosine-binding domain of Src family 
kinases, to p561cbs C-terminus. This binding appears to force the two lobes of the kinase 
domain closer together [209, 210]. Reppressed Src family kinases form another 
intermolecular interaction. The linker region between the SH2 domain and the kinase 
domain adopts a polyproline type-II helix (PP-II) that is bound by the SH3 domain, the 
polyproline-binding domain of Src family kinases. Both intermolecular interactions are 
thought to give the kinase more stability and may be events necessary to gain chaperone 
independence. This hypothesis predicts that oncogenic mutations that prevent the stable 
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inhibitory interaction of the SH3 and SH2 domains with the catalytic domain of Src-
family kinases would also show a requirement for conditional maintenance by Hsp90. 
The chaperone components are not interacting with the tyrosine 505 directly since 
the C-terminal lobe of the kinase domain, which includes the tyrosine 505, did not 
interact with any of the chaperone components. The N-terminal lobe was able to either 
immunoprecipitate with or co-immunoprecipitate with all of the chaperone components. 
What Hsp90 and its co-chaperones recognize in client proteins is still unknown although 
here we have localized the interaction site within a subdomain of the kinase catalytic 
domain. Currently clones are being made in our lab based on the molecular weight of 
bands identified from figures 10 and 11 of chapter 3. While these bands may only 
represent artifacts induced by treatment with puromycin and early release from the 
ribosome they may be useful for identifying high affinity binding motifs in known client 
kinases. 
The results presented here, as stated, was modeled in RRL and sci any interactions 
identified here need to be confirmed in T cells, the normal site of p561ck expression. This 
confirmation, however, will need to overcome technical barriers and so may never be 
feasible. One is the population of p561ck known to interact with Hsp90 machinery. Only 
immature p561ck appears to interact and depend on Hsp90 machinery for folding. This 
represents a very small pool of the overall p561ck in T cells. The pool of co-chaperones 
interacting with p561ck also is very small and the antibodies for most of these co-
chaperones are not very sensitive. A specific example of the short-comings in identifing 
these interactions using current methods and reagents is that a cell line that expresses 
p561ck at 30 times the normal levels (LSTRA) had to be used in order to detect its 
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interaction with just Hsp90, which is one of the most highly expressed proteins in the cell 
(1-2% of total cytosolic protein). Even using LSTRA cell extracts detection of the 
interaction between p561ck and Hsp90 required large quantities of cells to be cultured. 
RRL allows for the specific and controlled synthesis of a single radioactively labeled 
immature uniform population of protein product in a chaperone rich environment[26]. 
Nonetheless, the RRL model system is limited and sure to miss important protein 




The body of work presented here begins by showing an in vivo dependence of a 
kinase for chaperone function. The chaperone interactions with this kinase are then 
monitored and modeled from very early, during translation, to a mature active stable 
state, independent of chaperone interaction and function. 
GA affects immature p561ck and overall T cell biology 
The effects of the specific Hsp90 inhibitor, GA, on T cell biology and specifically 
on cellular p561ck showed that activated and proliferating T cells are more sensitive to GA 
toxicity, a result common to many chemotherapeutic drugs. The depletion of cellular 
p561ck suggests Hsp90 dependence in vivo, especially for the newly synthesized p561ck. A 
lysosomal degradation pathway induced by GA is implicated. The effects of GA on p561ck 
in T cells agree with a concurrent study using transfected p561ck. However, we utilized the 
Jurkat T cell line, which endogenously expresses p561c\ and allows for characterization in 
a more natural setting. 
Co-translational interactions 
The work focused on early interactions of p561ck with chaperones, due to the more 
pronounced dependence on Hsp90 shown by the newly synthesized p561ck in T cells. 
Using the RRL system to extend our study of p561ck interaction with chaperones we 
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compared the co-translational interactions of three different proteins. Only HRI showed 
interactions with Hsp90 and p50cdc37 while still on the ribosome. This may indicate a very 
early need of HRI for chaperone intervention. HRI activity is also very closely regulated 
since it regulates the very important process of protein translation initiation. 
Immature p561ck chaperone interactions in RRL 
The post-translational interactions of newly synthesized p561c\ as modeled in 
RRL, show that most of the same components necessary to reconstitue activatable steroid 
receptor complexes are also involved in early folding of p561ck·. These interactions are 
necessary for biogenesis of active kinase, but are not necessary to maintain mature kinase 
activity. However, mutant kinases appear to be more dependent on Hsps for activity. 
These results show that very minor changes can make a dramatic difference in protein 
stability. 
Concluding remarks 
Until recently protein folding by molecular chaperones, such as Hsp70 and Hsp90 
were thought to be restricted to stress related events. However, a better appreciation of 
the crowded environment of the cell and the potential pitfalls newly synthesized proteins 
encounter during de novo folding indicate Hsp70, Hsp90, and other chaperones play a 
more significant role in general protein folding than previously thought. It is also realized 
that chaperones are not merely involved in folding, but can also regulate the function of 
some substrates such as HRI, and steroid receptors, making it a target for 
pharmacological intervention. The central role of Hsp90 in many processes of 
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morphological evolutionary changes and a potential role in cancer cell evolution were 
recently suggested by Rutherford and Lindquist [211]. 
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